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Abstract
This study explored the effects of number of intrathecal chemotherapies and time off
therapy on cognitive, achievement, and neuropsychological functioning of post treatment
children with Acute Lymphocytic Leukemia (ALL). Participants consisted of sixteen sibling
pairs between the ages of eight and fourteen who were grouped into the high or low group for
number of intrathecal chemotherapies (IT), and then regrouped for high or low time off therapy
(TOT). Participants were administered a battery of cognitive, achievement, and
neuropsychological tests. Matched sibling difference scores from these tests were analyzed.
Results found that children with ALL performed in the average range, although below their
healthy siblings in some domains, indicating that treatments appear to be doing less harm than
anticipated from the past literature. Results indicate that on reading composite (comprehension
and pseudoword reading) and math reasoning the high IT children with ALL, when compared
with low IT children with ALL, performed more poorly than their healthy siblings. A large
effect size for intelligence quotient indicated that high IT children with ALL, when compared
with low IT children with ALL, performed more poorly than their healthy siblings. Large effect
sizes also were noted for time off therapy (TOT) for reading composite and math reasoning, with
the high TOT children with ALL performing more poorly than the low TOT children with ALL,
relative to their healthy siblings. Nevertheless, there is cause for optimism.
This study replicated prior research on the effects of high number of intrathecal
chemotherapies on the intellectual, reading, and math performance of children with ALL, with
late effects becoming most apparent at five or more years post therapy. However, post hoc
analyses cautioned that these results should be interpreted conservatively, given the study’s
methodological limitations.
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Cognitive, Academic, and Neuropsychological Effects of Treatment for
Children with Acute Lymphocytic Leukemia
Chapter 1: Introduction
According to the American Cancer Society, approximately 10,380 children under the age
of fifteen develop some form of cancer each year (American Cancer Society, 2016). In the
United States there are approximately 60,000 survivors of childhood cancer under the age of 15
(Siegel et al., 2012). Approximately 3,000 of these children are diagnosed with acute
lymphocytic leukemia (ALL), the most common of all childhood cancers. ALL is also one of the
most treatable childhood cancers, with current survivor estimates of 90% (American Cancer
Society, 2016). However, treatment comes with a price, as approximately 40% of children with
ALL experience a deficit in some aspect of neurocognitive functioning (Nathan et al., 2007).
Leukemia is a cancer of the blood that causes rapid mitosis (cell division) of immature
white blood cells. This rapid mitosis causes the bone marrow to fill up quickly with the
leukemia cells, leaving little room for platelets and red blood cells. These immature cells do not
perform the function of normal, healthy white blood cells and place the child at risk for death due
to overwhelming infection. The illness presents with bleeding, bruising, and anemia (Armstrong
& Mulhern, 1999). Because blood moves throughout all organs of the body, leukemia is known
to migrate into the central nervous system (CNS). Leukemia cells also are known to hibernate in
the CNS. Historically, the prognosis for children with leukemia was very poor when receiving
only systemic chemotherapies (chemotherapies given through intravenous injection, orally, or
intramuscularly), as these treatments could not pass through the blood-brain barrier and enter the
central nervous system. Survival rates increased when treatment protocols of the 1970s started to
include CNS radiation treatment, giving lifesaving treatment directly into the central nervous
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system. Therefore, all current leukemia treatment protocols require systemic chemotherapy and
some form of therapy to terminate leukemia cells in the CNS, the blood stream, and bone
marrow. These treatment protocols include cranial-spinal radiation, intrathecal chemotherapy
(chemotherapy treatments administered directly into the epidural space at the base of the spinal
cord, via a spinal tap), or stem cell bone marrow transplant.
Since the 1970s, researchers have examined the cognitive and educational impact of
childhood cancer and treatments (see Armstrong, Blumberg, & Toledano, 1999; Campbell et al.,
2007; Peterson et al., 2008; Robinson et al., 2009). During the 1970s and early 1980s, most
children with ALL received a treatment regimen consisting of cranial-spinal radiation, systemic
chemotherapy (SC) (administered orally, intravenously, or intramuscularly), and intrathecal
chemotherapy (IT) (Armstrong et al., 1999). These protocols were effective in curing 70 - 80%
of children. However, a series of studies showed high toxicity levels caused by these treatments,
resulting in considerable losses in intellectual, achievement, and information processing abilities.
Meadows et al. (1981) conducted one of the first comprehensive studies regarding longterm intellectual and achievement outcomes of post therapy children with ALL who received
cranial-spinal radiation treatment. All participants (n = 31) in this study received baseline testing
within the first month of diagnosis and, prior to receiving radiation therapy, they all tested in the
average range of intelligence. Twenty-eight of the participants were tested again 12-34 months
after treatment and eighteen were again tested three years later. Follow-up testing demonstrated
that the majority of the participants demonstrated lower global intellectual and academic
functioning than when first diagnosed. Participants with a baseline IQ between 86 – 109
averaged an 8 point drop in IQ at the time of follow-up testing. Participants with a baseline IQ
between 110 – 132 averaged a 23.5 point decrease at follow up testing. In addition, a significant
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age effect showed greater relative delays in intellectual functioning for younger than older
children. This was the first study to demonstrate that age at diagnosis coupled with cranial-spinal
radiation therapy (CRT) played an important role in detrimental cognitive late effects.
Following the influential work of Meadows et al. (1981), numerous studies in the 1980s
and 1990s focused on the relationship between cranial-spinal radiation therapy and
cognitive/achievement effects after children with ALL had completed treatment. Four factors
showed the strongest relationship with cognitive difficulties. Researchers found a consistent
pattern in the amount of time off therapy being correlated with greater negative effects.
Cognitive late effects most typically would present between two to five years off therapy and
then level off (Brown et al., 1992; Copeland et al., 1988; Jankovic et al., 1994). Research also
found strong evidence that children diagnosed and treated under the age of 5 were more likely to
have cognitive late effects than children diagnosed at older ages (Cousens, Waters, Said, &
Stevens, 1988). Additional research demonstrated links between gender and cognitive late
effects, with poorer outcomes for females (Robison et al., 1984; Waber, et al., 1990). Finally, a
number of studies found that higher doses of intrathecal chemotherapy were linked to greater
long-term cognitive deficits (Kingma, et al., 2002; Lansky, Cairns, & Zwarjies, 1984; Williams,
Ochs, Davis, & Daniel, 1986). Many of these earlier studies had methodological issues that
persist today when studying children who had been treated for ALL.
An important limitation with studying this population of children is that many studies
focusing on neuropsychological effects of treatment include low numbers of children with ALL.
For example, of the 28 studies in Campbell et al.’s (2007) meta-analysis of long-term
neuropsychological effects on survivors of childhood ALL, 14 studies had groups of ALL
children with fewer than 20 participants. Seven of the studies had groups of participants that
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ranged from 10 to 15 post therapy children with ALL. Studies with small sample sizes are
common when conducting a single site study with children with ALL, which create data analysis
and generalization issues. Another complicating factor is that children with the same type of
cancer may be treated on different protocols and receive different amounts of the same
chemotherapy agent, or very different chemotherapy agents. This presents an analysis problem
in studies with small sample sizes. Despite the preponderance of small n studies, Campbell’s
meta-analysis served to confirm the cognitive and academic late effects of treatments that
include cranial-spinal radiation, as well as methodological issues in designing such studies.
The studies from the 1980s and 1990s continued to find relationships between cranialspinal radiation therapy and cognitive and academic decrements. Given this evidence, the
leading pediatric association recommended treating children with low or standard risk ALL using
systemic and intrathecal chemotherapy, without cranial-spinal radiation therapy. They believed
these new protocols would eliminate the neurocognitive late effects experienced by children,
without compromising mortality rates. Protocols that excluded the use of radiation and only
included systemic chemotherapy (SC) and intrathecal chemotherapy (IT) were developed. These
protocols demonstrated effectiveness at curing leukemia at rates similar to protocols that
included cranial-spinal radiation. A large scale study by Mitby et al. (2003) estimated that
approximately 40% of survivors of childhood ALL would receive some special education
services during their school years, though causation was unclear. To what extent number of
intrathecal chemotherapies and time off therapy impact neurocognitive late effects needed
further exploration, with more adequate controls. Regardless, this shift in treatment protocols
then led to a number of studies that evaluated the effects of leukemia SC and IT chemotherapy
protocols on toxicity of treatment and neurocognitive late effects, as well as the relationship of
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time off therapy to the appearance of these weaknesses. Evidence from many of these
studies found that large doses of IT chemotherapy adversely affects brain structures, particularly
white matter, which is believed to lead to information processing challenges, which cause the
weaknesses in achievement functioning.
The current study was designed to assess the neurocognitive outcomes of non-radiation
ALL treatment in relation to number of intrathecal injections and time off therapy, while using
healthy siblings as controls for the cancer experience. It was predicted that participants with
ALL in the high IT and high TOT groups would show greater neurocognitive weaknesses than
the low IT and low TOT groups, when compared to their healthy siblings. This study expanded
on the achievement and neuropsychological variables measured in prior studies. It also
controlled for family factors by using siblings as controls. The results were expected to have
implications for treatment protocols and psycho-educational interventions that would allay
predictable weaknesses related to ALL therapy.
Chapter 2 presents a more in-depth understanding of childhood ALL treatment and the
effects of cranial-spinal radiation and/or, systemic and intrathecal chemotherapy, on the
cognitive, academic achievement, and neuropsychological outcomes for children who had been
treated for ALL.
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Chapter 2: Literature Review
Due to the negative cognitive, achievement, and neuropsychological outcomes of the
treatment protocols that included cranial-spinal radiation treatment, treatment of childhood ALL
shifted to systemic and intrathecal chemotherapy protocols that did not include any radiation.
This review will explore the literature comparing the neurocognitive outcomes of protocols that
included cranial-spinal radiation to those that did not. This review also will explore the systemic
and intrathecal treatment literature that focuses on neurocognitive late effects for children with
acute lymphocytic leukemia.
Effects of Cranial-Spinal Radiation Treatment Compared to Systemic and Intrathecal
Chemotherapy Treatment
Smibert, Anderson, Godber, and Ekert (1996) conducted one of the first studies to
compare cranial-spinal radiation to systemic and intrathecal chemotherapy treatment approaches.
This study was interested in the long-term intellectual and academic outcomes for post therapy
children with ALL. A large sample (n = 100) of childhood leukemia participants treated with
both irradiation and chemotherapy was compared to a healthy control group (n = 100) and a
comparison group of children with mixed cancers (n = 50) who received chemotherapy, but not
radiation, as part of their therapy. The study found that children who received cranial-spinal
radiation performed more poorly on measures of intelligence and academic achievement than
either the healthy control group or the mixed cancer comparison group that received SC or SC +
IT but no radiation. Additionally, a younger age at treatment (< 5 years) and a higher amount of
radiation were predictive of poorer intellectual and academic performance. The participants who
received SC or SC +IT chemotherapy without radiation performed similarly to the healthy
control group. One limitation of the Smibert et al. study was that the chemotherapy only group (n
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= 50) was a mix of different childhood cancers, some who received intrathecal chemotherapy (n
= 24) and others only systemic chemotherapy (n = 26). Similar findings were noted by several
other studies (Barrera, Shaw, Speechley, Maunsell, & Pogany, 2005; Langer et al., 2002;
Raymond-Speden, Tripp, & Lawrence, 2000; Spiegler et al., 2006). While all of these studies
used comparison groups, none utilized any type of matched controls; thus demographic factors
such as socio-economic status (SES), parent education level, gender, and age were left
unaccounted for. Regardless of the methodological limitations, significant negative effects of
cranial-spinal radiation on cognition and academic achievement when compared with SC and IT
treatment was undeniable.
Hill et al. (1998) reported similar findings when comparing long-term effects on children
with ALL treated with systemic and intrathecal chemotherapy (specifically, methotrexate), with
and without cranial-spinal radiation (n = 110). This study also focused on psychosocial long-term
effects, as participants were between 14 years - 4 months to 14 years - 9 months since the time of
diagnosis. In addition to poorer academic outcomes, this study found that children with ALL
who received systemic and intrathecal chemotherapy and radiation treatment reported having a
poorer self-image and greater psychological stress than children with ALL who received
systemic and intrathecal chemotherapy treatment without radiation. This study used subjective,
self report psychosocial measures to examine psychosocial outcomes for children with ALL.
In addition to intellectual and academic difficulties, researchers have found gender
specific effects of ALL treatment as well. Précourt et al. (2002) were interested in the long-term
effects of verbal learning ability for female children with ALL. They compared girls who
received systemic chemotherapies, intrathecal chemotherapies, and cranial-spinal radiation (n =
9) to girls who received only systemic chemotherapies and intrathecal chemotherapies (n = 10).
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The study used a healthy control group of girls (n = 10). Only the group receiving systemic and
intrathecal chemotherapies plus cranial-spinal radiation performed more poorly than the control
group on verbal learning and passage comprehension.
Around this same time, researchers became particularly concerned with the late effects of
one chemotherapy agent, IT methotrexate. This chemotherapy agent was found to cause greater
cognitive late effects in female children with ALL than other chemotherapies, when injected into
the central nervous system. However, IT methotrexate also had been found more effective in
treating the disease (Mulhern, Fairclough, & Ochs, 1991; Williams, Ochs, Davis, & Daniel,
1986). Methotrexate, when used as a systemic chemotherapy agent, had not been found to cause
neurocognitive late effects in children being treated for cancers other than leukemia (Anderson,
Smibert, Ekert, & Godber, 1994; Lansky et al., 1984).
Looking at neuropsychological outcomes of treatment, Campbell et al. (2007) conducted
a meta-analysis of childhood ALL studies that used systemic and intrathecal chemotherapy, with
or without cranial-spinal radiation. Twenty-eight studies from 1980–2004 were used. The
participants were in first remission and nationally normed psychometric measures were normed
nationally. The meta-analysis found evidence that cranial-spinal radiation, in combination with
systemic and intrathecal chemotherapy, has a detrimental effect on overall intellectual
functioning when compared with non-ALL controls. Age at time of diagnosis and time off
therapy provided mixed results in this meta-analysis.
A national Canadian study (Barrera, Shaw, Speechley, Maunsell, & Pogany, 2005)
reviewed the educational and social outcomes for survivors of various childhood cancers (n =
800) and compared these outcomes with healthy age and gender-matched controls (n = 923). The
findings indicate that survivors who received central nervous system treatments—such as cranial
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radiation alone, or cranial radiation together with systemic chemotherapy and intrathecal
chemotherapy, or systemic chemotherapy and intrathecal chemotherapy—were more likely to
struggle in school, be placed in special education, and be at greater risk for academic and social
difficulties at school than survivors of childhood cancers that required no central nervous system
treatment. Of the 800 childhood cancer survivors, 293 were leukemia survivors. The leukemia
survivors were considerably more likely than the control group to be enrolled in special
education, be identified with a specific learning disability, repeat a grade, and have other school
problems. This study found that one of the academic areas in which survivors struggled was
English, but did not distinguish if reading and writing were of particular concern for this
population. Survivors with central nervous system tumors (such as brain tumors) and who
received cranial radiation demonstrated the greatest difference from the control population,
followed by participants who received central nervous system treatment for leukemia. Leukemia
patients treated with cranial radiation were more likely than those treated with systemic and
intrathecal chemotherapy to demonstrate the above school issues.
Some investigators focused more particularly on how survivors’ attention and
information processing impact their academic and social experiences. Spiegler et al. (2006)
compared neurocognitive outcomes of ALL treatment with or without cranial-spinal radiation.
The study also included two groups that received systemic and intrathecal chemotherapy, but no
radiation: the high dose methotrexate group (n = 32) (HD-MTX), and the very high dose
methotrexate group (n = 22) (VHD-MTX). An additional group received cranial-spinal radiation
but no intrathecal chemotherapy (n = 25) (CRT). As with previous research, the CRT group
performed significantly worse than the HD-MTX and the VHD-MTX groups on intelligence,
memory, and academic measures. On an attention measure, children with ALL treated with HD-
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MTX and VHD-MTX protocols performed close to the population norms, with the exception of
greater impulsivity on the Delay task of the Gordon Diagnostic System.
Over time, treatment protocols for children with ALL have excluded cranial-spinal
radiation because of its strong association with cognitive late effects. Investigations
subsequently explored the more subtle difficulties of post therapy children with ALL who
received intrathecal and systemic chemotherapy treatments without cranial-spinal radiation.
Effects of Systemic and Intrathecal Chemotherapy Treatment
The treatment effects of childhood ALL chemotherapy-only protocols is an important
area of study. All childhood ALL treatment protocols require some IT chemotherapy to achieve
curative effects. The first treatments of this kind began in the mid-1980s. By eliminating cranial
radiation (CRT) from the treatment regimen, it was hoped that children with ALL would not
experience any neurocognitive late effects. However, research on combined systemic and
intrathecal treatments made clear that children with ALL were still at risk for neurocognitive and
achievement delays, even when treated without cranial-spinal irradiation (Armstrong et al., 1999;
Butler & Copeland, 2002; Cousens et al., 1998; Essig et al., 2014; Hill et al., 1998). The focus of
late effects research sought to understand which treatment variables most predicted specific
neurocognitive and educational risk areas for survivors treated with systemic and intrathecal
chemotherapy.
Based on findings from the 1990s, ALL researchers increasingly controlled for age,
gender, cumulative dosage, and time off therapy to better understand the neurocognitive and
achievement decrements revealed by the research. Research began to focus more specifically on
processing issues such as attention, memory, visual-motor performance, and processing speed.
Among the sizable number of studies conducted in the 1990s and early 2000s, the neurocognitive
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late effects findings often were mixed. The findings of studies that targeted specific aspects of
information processing are reviewed below.
Intelligence and achievement.
A national study by von der Weid, Mosimann, and Hirt (2003) compared 132 children
with ALL who had received systemic and intrathecal chemotherapy treatments in Switzerland to
100 childhood cancer survivors who received no central nervous system treatment. The findings
demonstrated both age (less than six at age of diagnosis) and gender (female) as risk factors for
decreased intellectual functioning in children with ALL after treatment was concluded. A metaanalysis by Peterson et al. (2008) found relative delays in intelligence, mathematics, reading,
attention, perceptual reasoning, processing speed, verbal memory, and executive functioning
among post therapy children with ALL. Campbell et al. (2007) and Lyer, Balsamo, Bracken, and
Kadan-Kottick (2016) also found weaknesses in intelligence, academic achievement, and several
neuropsychological domains.
Espy et al. (2001) was one of the first studies to use growth curve analysis to explore
treatment-related neuropsychological outcomes in children treated with SC + IT protocols. The
investigators administered a psycho-educational assessment battery that included traditional tests
of intelligence and achievement and a comprehensive memory and processing battery.
Participants were tested at eight months, two, three, and four years post-diagnosis. Compared to
test norms, the investigators found declines in arithmetic skills, visual-motor integration, and
verbal fluency for children with ALL at four years post therapy. There was no relationship
between the rate of decline and the specific SC + IT protocol.
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Attention.
Mennes et al. (2005) focused on attention and the processing speed of children with ALL.
Twenty-three post therapy children with ALL who were treated on two European protocols that
included systemic and intrathecal chemotherapies were compared to 23 age and gender matched
controls. No difference was found between the two groups on sustained attention, inhibition,
organization tasks, and simple baseline speed (the study used a simple mouse click response time
activity). However, on more complex executive function tasks, children with ALL performed
significantly worse than their healthy peers on focused attention tasks, memory recall, and
memory search. Carey et al. (2008) and Butler et al. (2016) also found that post therapy children
with ALL who had received systemic and intrathecal chemotherapies demonstrated lower
performance on attention tasks, mental flexibility, visual-construction skills, and math
achievement than the healthy control group.
Fine-motor.
In a sibling control study, Jansen et al. (2008) focused on the neuropsychological
function over time of children with ALL who had received systemic and intrathecal
chemotherapies. Forty-nine children with ALL were compared to 29 healthy siblings on finemotor and perceptual functioning, memory and learning, sustained attention, speed, and
executive functioning, at two time points: 3 to 6 months off therapy and 2.5 years off therapy.
The study had two significant findings: 1) children with ALL demonstrated significantly weaker
fine-motor skills over time than the sibling control group, and 2) children with ALL who
expressed greater pain or fatigue during treatment demonstrated poorer sustained attention years
after completion of treatment, in comparison to the sibling control group.
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Memory.
Kingma et al. (2002) conducted a seven-year longitudinal study that focused on memory,
intelligence, attention, processing speed, and motor skills of 20 children with ALL who had
received systemic and intrathecal chemotherapy. Compared to a healthy control group, findings
demonstrated relative delays in memory and fine-motor ability for post therapy children with
ALL. In a similarly designed study, Kaemingk, Carey, Moore, Herzer, and Hutter (2004)
compared children with ALL who had received systemic and intrathecal chemotherapy
treatment with 15 healthy controls. The control group was comprised of matched age and gender
participants utilizing siblings and friends. While the children with ALL performed mostly in the
normal range, relative difficulties in memory, psychomotor speed, math calculation, math
reasoning, attention, and visual-motor ability were noted.
In a small single site study, Hill et al. (1998) controlled for age, gender, SES and
handedness to strengthen their study. This was one of the first studies to use a normed memory
measure (the Wide Range Assessment of Memory and Learning). The research focused on the
impact of systemic and intrathecal treatment on visual and verbal memory. Ten post therapy
children with ALL were compared with ten healthy controls. The study showed relative delays in
visual and verbal short-term memory, planning, and inattention issues for the children with ALL,
in addition to 10-20 point deficits in intellectual scores.
In Ashford et al.’s (2010) childhood ALL study of working memory, post therapy
children with ALL were placed into either low- or high-risk groups based on cumulative
treatment dosage and number of intrathecal treatments: 13 to 18 treatments in the low risk group
and 16 to 25 treatments in the high-risk group. This study found that the high-risk treatment
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group underperformed when compared to normative data on tests of Digit Span Forward (DSF),
Digit Span Backwards (DSB), and Total Digit Span (TDS). The low-risk treatment group had
difficulty with the Digit Span Backwards only.
Processing speed.
Mahone, Prahme, Ruble, Mostofsky, and Schwartz (2007) compared the motor
processing speed of children with ALL (n = 22), who had received systemic and intrathecal
chemotherapy treatment, with age and gender matched healthy controls. Participants completed
computer-based motor timed tasks as part of a larger neuropsychological battery. The ALL group
performed more poorly than the control group on motor processing speed and in ability to
estimate durations of time. Other studies also have noted relative delays with visual-motor speed
(Buizer et al., 2005; Cheung & Krull, 2016; Kaemingk et al., 2004; Kingma et al., 2002).
Using a sibling comparison group, Reeves et al. (2007) assessed whether post therapy
children with ALL have delays in processing speed and if this relates to behavioral symptoms.
Eighty post therapy children with ALL and 19 sibling controls were studied using processing
speed and achievement measures, and an abbreviated IQ test (three WISC-IV subtests:
Information, Similarities, and Block Design). Behavior was measured using the Child Behavior
Checklist (CBCL). The study found that children who had been treated for ALL had more
processing speed delays than their sibling controls. The siblings scored higher than the ALL
group on all measures of intelligence and academics, with the exception of numerical operations.
In summary, the findings from research on cognitive, achievement, and information
processing functioning of children with ALL who had received SC and IT treatment suggests
they are at greater risk for mild difficulties in intellectual functioning, academic achievement,
memory, fine-motor skills, processing speed, and attention even without receiving cranial
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radiation therapy. Today, the combined SC and IT therapy remains the most common treatment
approach for childhood ALL (Anderson et al., 2009; Brown et al., 1998; Copeland et al., 1996;
Espy et al., 2002; Lansky et al., 1984). Although lifesaving, these treatments come with
neurocognitive risks. Therefore, continued study of neurocognitive outcomes for children with
ALL is necessary.
The findings from these studies raise questions about whether there are ways that the
medical community can modify protocols and intervene preventatively if ALL treatment late
effects are likely. If not, are there ways that educators and therapists can monitor, prevent, and
remediate weaknesses more effectively? Are there therapy protocols that have less negative
outcomes? To better understand the relationship between treatment and cognitive, academic and
neuropsychological functioning, researchers have studied the effects of time off therapy, and
they are increasingly utilizing a combination of brain imaging and neuropsychological testing to
research these complicated effects.
Time off Therapy Effects of Systemic and Intrathecal Chemotherapy
Time off therapy has continued to be a focus of study, as neurocognitive and achievement
delays may not be visible immediately after treatment, but do become evident over time.
Copeland, Moore III, Francis, Geffee and Culbert (1996), for example, compared the cognitive
and academic effects experienced by 51 children with ALL, who had received systemic and
intrathecal chemotherapy treatment, to 48 children with other cancers who had received only
systemic chemotherapy. Intelligence, memory, language, achievement, fine-motor, perceptualmotor, and tactile-spatial skills were assessed. Both groups showed declines on achievement
scores, with time off therapy (TOT) becoming an important variable by three years post
treatment. For the children with ALL, being treated at a young age (< 5 years) and the more time
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off therapy (5 to 11 years), the greater the decline in perceptual-motor ability. On the
performance intelligence quotient, children with ALL who had received systemic and intrathecal
chemotherapy treatments scored approximately 10 points lower than their childhood cancer
counterparts who received no central nervous system treatment. During the baseline year, which
began at the time of diagnosis, the IQ scores of both groups had been equivalent.
Brown et al.’s (1996) study compared children with ALL who had been treated with
systemic and intrathecal chemotherapy (n = 38) to children with other childhood cancer
diagnoses who received only systemic chemotherapy treatment (n = 25). For the children with
ALL, a steady decline was evident on the reading, writing, and arithmetic sections of the Wide
Range Achievement Test over the four-year period from diagnosis. There were no cognitive or
achievement deficits for the mixed-cancer comparison group. The declines for the post therapy
children with ALL were attributed to the intrathecal chemotherapy treatment.
In another study, Brown et al. (1998) examined the cognitive and academic late effects
among 47 children and adolescents with ALL who had been treated with the same systemic and
IT chemotherapy protocol. All of the participants had been off treatment for two to seven years
at the time of assessment. The study found a negative gender effect on nonverbal tasks for girls
who were treated for ALL, when compared to the test’s normative data and to boys treated with
the same protocol. The females with ALL scored close to one standard deviation below the mean
on performance tasks, whereas the males with ALL scored within low average to average ranges.
A study by Mulhern, Fairclough, and Ochs (1991) found that children with ALL who had
received SC and IT therapy had average intelligence and achievement scores at one year off
therapy. At four years off therapy intelligence scores held stable, but achievement scores, though
still in the average range, had declined. In a similar study, Ochs et al. (1991) found that at a mean
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time of six years off therapy, children with ALL showed decreases in Full Scale IQ and Verbal
IQ scores, as well as math achievement. Late effects for achievement began to show sometime
between two and four years, with IQ late effects presenting between four and six years posttherapy.
Espy et al. (2001) too found that children with ALL demonstrated declines in verbal
fluency, math, and visual-motor processing skills if they were more than two years off therapy.
In their study, Kingma, Van Dommelen, and Mooyaart (2001) studied late effects at two time
points: 3-6 months post treatment (T1) and approximately 2.5 years post treatment (T2). No
intellectual changes were found from T1 to T2, but auditory memory and fine-motor difficulties
did become apparent at T2. In a study published a year later, Kingma et al. (2002) report that at 5
years off therapy the children with ALL (n = 20) had lower Verbal IQ and attention when
compared to the healthy control group.
Finally, Jansen et al. (2006), Lyer et al. (2016), and Nathan et al. (2006) found small
decreases over time in intellectual function for children with ALL. These studies were
longitudinal in nature and focused on time off therapy of under two years post treatment and
again at 5 + years post treatment. Collectively, these studies suggest there is a likelihood of late
effects becoming apparent in intelligence, achievement, perceptual-motor skills, auditory
memory, and attention skills at approximately 5 or more years post therapy. Sometimes effects
present as early as two years off treatment on verbal fluency, spelling, reading, math, visualmotor, auditory memory, and fine-motor skills.
These studies were critical to the understanding that, despite the exclusion of cranialspinal radiation as part of curative therapy for childhood ALL, systemic and intrathecal
chemotherapy combined can still cause skill decrements, especially as time off therapy increases.
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These studies provide some depth of knowledge regarding neurocognitive and achievement late
effects among children with ALL who had been treated with SC and IT chemotherapy. More
recently, research has approached the issue of late effects of childhood ALL by utilizing more
extensive neuropsychological batteries together with brain imaging techniques.
Brain Physiology Research on Post Therapy Children with ALL
As the neurocognitive effects of ALL systemic and intrathecal chemotherapy treatment
have become evident, understanding the biological mechanisms that underpin these changes has
become a priority. The brain is the primary organ of interest for children with ALL in relation to
late effects. What is unclear is which biological system(s) within the brain are responsible for
cognitive difficulties faced by ALL survivors. Among the more robust theories is that ALL
treatments may affect brain matter in ways that make cognitive development more difficult. The
brain consists of what is commonly referred to as white and gray matter. White matter is
important because its neuron networks support messages being passed from one section of the
brain (gray matter) to another. A prevailing theory is that damage to the white matter due to
radiation or chemotherapy may disrupt this network (Reddick et al., 2003).
To best research changes in brain structures, studies primarily have utilized MRIs, which
create static images of the participant’s white and gray matter. For example, Montour-Proulx et
al. (2005) conducted a study that included traditional MRI imaging technology for children with
ALL who had been treated with SC and IT. This study used Growth Curve Analysis to study
how participants (n = 24) performed on measures of intelligence and memory. The advantage of
using this regression technique is that the researchers could analyze both group and individual
effects over time. This study took place over two time periods: Time 1 was while on treatment,
and Time 2 was sometime between 9 months to 2.5 years off therapy. The results of this study
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demonstrated a reduction in white matter over the two time points that correlated with a
significant reduction in Performance IQ scores.
Reddick et al. (2006) utilized imaging technology with neuropsychological testing and
demonstrated that post therapy children with ALL between the ages of six and eighteen (n = 112)
had neurocognitive delays and reduced white matter associated with those relative delays, when
compared to healthy siblings (n = 33). The findings demonstrated statistically significant
academic and attention delays for the children with ALL, who received cranial-spinal radiation
plus systemic and intrathecal chemotherapy. Attention delays were more than one SD below the
norm. Regarding the white matter, participants who received systemic and intrathecal
chemotherapy without radiation had considerably more white matter than their peers treated with
chemotherapy and cranial-spinal radiation, but both groups had less white matter than the healthy
sibling controls. Smaller white matter volumes were associated with relative delays in attention,
IQ, and academics. More aggressive treatments produced more detrimental physiological and
cognitive outcomes.
Ashford et al. (2010) conducted the only brain imaging study that focused on the number
of ITs, as they relate to neuropsychological outcomes. Their study examined the difference in
white matter volumes between a high IT (16-25) and a low IT (13-18) group of post therapy
children with ALL. IT groupings were based on a combination of number of ITs and total dosage
of chemotherapy. The findings indicated that the high IT group exhibited a greater risk for
leukoencephalopathy (white matter disease), working memory weaknesses, and attentional
difficulties.
Other structural differences in the brains of children treated for ALL have been suggested
by Lesnik, Ciesielski, Hart, Benzel, and Sanders (1998). Lesnik et al. conducted an imaging
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study of 6-13 year old childhood participants with ALL (n = 10) who had received systemic and
intrathecal chemotherapy. Results were compared to matched age and gender controls. Structural
brain differences in children with ALL demonstrated reduction in both left and right prefrontal
cortical areas, which corresponded with delays on tasks of visual-spatial attention, short-term
memory, and visual-motor organization.
Oxidized cerebral spinal fluid is also implicated in delays that follow SC + IT treatment
for ALL. Caron et al. (2009) measured oxidative stress (the body’s increase in oxidizing of
blood and a decrease in levels of antioxidants) over the first two years of treatment by collecting
spinal fluid during scheduled lumbar punctures, and then analyzing the oxidative levels in the
cranial spinal fluid. Executive functioning was tested over a three-year period after the
completion of therapy. The study found correlations between higher oxidative stress and lower
executive functioning at the two year post-treatment point of the study. In addition, there was a
significant correlation between younger age at diagnosis, higher oxidative stress levels, and
lower executive functioning ability. How oxidative stress levels might impact the brain is
unclear, but the findings overall indicate that children with ALL must cope with an array of
physiological changes that are detrimental to their cognitive functioning.
In contrast to an MRI of the brain, which is a static image, functional MRIs (fMRI)
provide images of the brain in an active state. Using fMRI, in conjunction with an executive
functioning cognitive rehabilitation curriculum, Kesler, Lacayo, and Jo (2011) conducted a study
with 23 post therapy children with ALL. This study concluded that the cognitive rehabilitation
curriculum improved executive function and memory skills, based on neuropsychological test
changes (processing speed, sort test, verbal and picture memory) as well as brain activation as
noted in the fMRI (increases in dorsal lateral prefrontal cortex activation).
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Robinson et al. (2010) utilized fMRIs to examine working memory and executive
functioning in children with ALL who had received systemic and intrathecal chemotherapy
between the ages of 10 to 16 years old (n = 8). Controls included age and gender matched
healthy peers (n = 7). The study found that children with ALL did more poorly on tasks of
working memory accuracy and had greater brain activity when focusing on working memory
tasks. The dorsolateral and ventrolateral prefrontal cortex showed substantial activation during
these tasks. In addition, the dorsal and ventral anterior cingulate cortex (involved in problem
solving, motivation, and assessing emotional information) demonstrated larger activation on
error monitoring tasks. Both of these findings suggest that compensatory activation was needed
in these brain regions to complete executive functioning tasks.
In summary, many of the imaging studies of children who had been treated for ALL
relate their changes in brain state and function to decrements in neuropsychological functioning.
These decrements are associated with physiological effects from treatment. Taken together, the
imaging and neurocognitive research has provided stakeholders with a more complete
understanding of the cognitive challenges faced by post therapy children with ALL on a daily
basis. Potential difficulties in academic performance (math and reading), intellectual functioning,
processing difficulties (visual-motor, fine-motor, and processing speed), short-term and working
memory, and difficulties with executive functioning skills (planning and organization, attention,
and multistep problem solving) are possible effects of chemotherapy treatment. More research is
necessary to better predict which children with ALL are likely to struggle and when. Exploring
ways to minimize negative effects and predict those children at greatest risk, without
compromising treatment efficacy, is an important task. These findings offer areas ripe for
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research on how to support children’s ability to develop compensatory neural processes that
might mitigate some of the negative physiological effects of treatment.
Summary of Childhood ALL Neurocognitive and Achievement Research
Lifesaving treatment for childhood acute lymphocytic leukemia has been ongoing since
the 1970s. The success rates and reduction of long-term effects for children with ALL have
increased dramatically over the past 50 years as treatment protocols shifted from including
cranial-spinal radiation, intrathecal, and systemic chemotherapies, to less toxic intrathecal and
systemic chemotherapy only protocols. Factors such as 1) a younger age at diagnosis and initial
treatment (with females being more susceptible than males), 2) time off therapy with
neurocognitive late effects presenting at approximately five or more years off therapy, but
sometimes sooner, and 3) higher cumulative doses and numbers of intrathecal chemotherapy
treatments often have been associated with negative neurocognitive effects. However the
majority of the findings from these studies demonstrate that children with ALL typically perform
in the average range, albeit significantly lower then their comparison groups (Ashford et al.,
2010; Brown et al., 1996; Buizer et al., 2005; Cheang & Krull 2015; Espy et al., 2001; Essing et
al., 2014; Jansen et al., 2008; Kaemingk et al., 2004; Kanellopoulos et al., 2016; Lyer et al.,
2016; Reddick et al., 2006; Waber et al., 2007). Although recent research has become more
specific regarding the effects of chemotherapy, more studies are needed to better understand
these cognitive, educational, and neuropsychological outcomes in children treated for ALL.
In pursuing this line of research, adequate control groups are essential. Some studies
have had no controls, some do match on several variables, and others use mixed control groups
of friends, siblings or convenience samples of healthy peers. It is common to simply compare the
performance of children with ALL to standardized test norms. Thus far, siblings have been used
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sparingly as a healthy control group in childhood cancer research. A review of the literature
reveals that only six empirical studies of SC + IT treatment effects since the 1980s have included
siblings of children with ALL (Jansen et al., 2008; Kaemingk et al., 2004; Mitby et al., 2003;
Reddick et al., 2006; Reeves et al., 2007; Rodgers, Marckus, Kearns, & Windebank, 2003). Of
these six, three used a battery of neurocognitive tests, including intelligence, achievement, and
executive functioning assessment (Jansen et al. 2008; Reddick et al., 2006; Reeves et al., 2007).
All three of these studies were whole-group comparisons and used a smaller number of siblings
than the number of children with ALL in the studies, primarily for the purpose of ensuring that
basic demographic and intellectual functioning was controlled. The use of healthy sibling
controls, one-to-one matches, has the advantage of controlling for SES, race/ethnicity, parent
education, genetics, home climate, and the shared crisis experience. Ideally, this research would
be best suited to a twin study, but finding sets of twins where one is diagnosed with leukemia
and one is not is almost unheard of.
Taken as a whole, studies of the neurocognitive and achievement effects of childhood
ALL treatments leave little room for questioning the general phenomenon of long-term effects.
Using a range of methodological approaches, these studies established that many children who
undergo treatment for ALL face later learning challenges, even though they may score in the
average range on many of the neuropsychological and achievement measures.
Although childhood cancer treatment has made great strides in increasing life expectancy
and reducing overall neurocognitive deficits due to treatment, intellectual, academic and
neuropsychological relative delays remain. These delays are milder than treatments that include
cranial radiation, but they nevertheless remain persistent, subtle, and varied. Because of the set of
findings around the late-term neurocognitive effects for children with ALL, it is critical that we
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continue to deepen our understanding of the consequences of various combinations of
treatments. This understanding can lead to revising treatment protocols and a greater focus on
early intervention for predictable cognitive, achievement, and neuropsychological weaknesses.

Current Study
The primary research question in the current study was how high vs. low numbers of
intrathecal treatments, and high vs. low time off therapy relate to specific cognitive,
achievement, and neuropsychological outcomes for children who had been treated for ALL,
when compared with their siblings. This study examined the effects of ALL treatment by
creating high and low IT groups based on the number of intrathecal chemotherapies (< 20 or >
20). High and low time off therapy groups also were created based on five or more, vs. below
five, years off therapy. The IT and TOT group cut offs were based on research showing more
neurocognitive late effects with 20 or more ITs, or at 5 or more years off treatment.
The current study used a healthy sibling control group in order to better control for the
family’s cancer experience, as well as for demographics, such as SES and parent educational
level. These factors have seldom been considered when studying late effects among children
with ALL. Previous research comparing post therapy children with ALL to their healthy sibling
counterparts has found differences in intellectual, achievement, processing speed, memory, finemotor, visual-motor and attention domains (Janson et al., 2008; Kaemingk et al., 2004; Reddick
et al., 2006; Reeves et al., 2007; Rodgers et al., 1999). The current study explored these domains
but also added some measures seldom used in ALL studies: Executive Functioning Scale,
Reading Comprehension, Phonemic Awareness, Math Reasoning, and Writing Sample.
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Knowing that neurocognitive late effects can appear as early as two years off therapy
and become even more evident at five or more years off therapy, this study examined how
weaknesses would manifest in children with ALL with high vs. low time off therapy and with
high vs. low numbers of intrathecal treatments. It was predicted that children with ALL who
were classified as high IT or high TOT would show greater weaknesses on the study’s measures
than those in the low IT or low TOT groups, when compared with their healthy siblings.
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Chapter 3: Method
Rationale for the Method
This study has taken advantage of the controls inherent in sibling controlled research
designs. The primary advantage of this design is the ability to vary one aspect of the environment
(childhood cancer treatment based on number of intrathecal chemotherapies or time off therapy)
while keeping much of the environment similar (home life, school, SES, and partial genetic
control) (Donovan and Susser, 2011). This study design allows for exploration of whether
analyzing sibling difference scores is helpful to statistical analysis when sample size is small. To
date, no studies of children with ALL have used sibling difference scores for the data analysis.
This study divided participants into a high and low group based on number of intrathecal
chemotherapy treatments, and a high and low group based on time off therapy, in order to
explore late effects on intelligence, academic achievement, and neuropsychological functioning
among children treated for ALL. In addition to using measures common in late effect research
(intelligence, verbal memory, executive functioning, attention, processing speed), this study also
added measures of prose writing, math reasoning, pseudoword reading, reading comprehension,
and parent rating of executive functioning.
Participants
Post therapy children with ALL and their healthy siblings were recruited from
Tomorrows Children’s Institute. Sixteen families agreed to have both the child with ALL and a
healthy sibling participate. Thirteen of the sixteen families were from Northern New Jersey and
from either middle-class (average household income of $60,000 – $90,000) or upper middleclass towns (average household income of $91,000 or more). All but one family identified as
white. In total, 32 participants between the ages of 8 - 14 participated in this study. Children
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with ALL ranged in age from 8 years – 5 months to 14 years - 9-months, with a mean age of 11
years -6 months. Healthy siblings ranged in age from 8 years - 0-months to 14 years - 7-months
with a mean age of 11 years – 3 months. The average age for the children with ALL in this study
was 142 months, while the average age for the healthy siblings participating in this study was
138 months. Healthy siblings with any documented attention, learning, or cognitive disability
were not permitted to participate in this study. The children with ALL had been diagnosed,
treated, and/or were currently followed by the Department of Pediatrics at the Joseph M. Sanzari
Children’s Hospital at Hackensack University Medical Center. All of the participants with ALL
received both intrathecal and systemic chemotherapy treatments that included methotrexate
chemotherapy, using one of four different childhood cancer protocols. All four protocols used
intrathecal methotrexate, but three included two additional intrathecal medications. Four
potentially toxic systemic drugs were common to all protocols. One protocol added a 5th drug,
another added a 6th drug, and one added a 7th and 8th drug.
This study included children with ALL between the ages of eight- and fourteen-years-old
who were treated with systemic (SC) and intrathecal (IT) chemotherapy (no radiation therapy),
and who had been off treatment for at least two years with no relapse. This combination of SC
and IT is the most commonly used therapy for childhood ALL and research has consistently
demonstrated that IT chemotherapy is linked to intellectual, cognitive, and information
processing delays (Anderson et al., 2009; Brown et al., 1998; Copeland et al., 1996; Lansky et
al., 1984).
This study used 20 and above as the high IT group requirement, and five or more years
off therapy as the high time off therapy group requirement. Because of the small sample size and
use of four different treatment protocols, the cumulative dosage approach to classifying high vs.
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low IT was not possible. Therefore, this study took an approach used in two prior studies,
estimating high and low dosage levels from the number of ITs. Pui et al. (2003) extrapolated
from their meta-analysis that 20 ITs is a likely threshold for increased risk of long-term cognitive
effects. In addition, Ashford et al., (2010) conducted a study which grouped participants based
on biological factors on MRI scans, number of intrathecal treatments, and cumulative dosage of
chemotherapies. Participants in Ashford et al.’s high risk group (16-25 ITs and greater
cumulative dosage) performed more poorly on working memory tasks than participants who
received lower numbers of IT (13-18) and lower cumulative dosage. In the current study, using
the 20 IT cut off resulted in seven children with ALL being in the high IT group and nine being
in the low IT group, with a sample mean for ITs of 18.81 (SD = 2.56). This study compared post
therapy children with ALL with 20 or above ITs to those with 19 and fewer ITs. The field of
childhood ALL research has been moving toward decreasing the amount of toxicity children
receive, by decreasing both total number of ITs and cumulative dosage of chemotherapies. This
is reflected in the study’s sample, where younger children with ALL were more prevalent in the
low IT groups. This study excluded children with ALL who had received cranial-spinal radiation
as part of their ALL treatment. Children with ALL also were excluded if they had any relapse or
any secondary cancer. Finally, no children who had been off treatment for ALL for less than 24
months were permitted to participate, as prior studies found that it is around age two that some
late effects of treatment begin to appear.
Based on literature showing that five years off therapy reveals more marked late effects
on neurocognition than fewer years off therapy (Espy et al., 2001; Kingma et al., 2002; Nathan et
al., 2007), five years or more off therapy was set as the high TOT group requirement. Children
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off therapy for less than five years were categorized in the low TOT group. This resulted in nine
children in the high TOT group and seven in the low TOT group.
Healthy siblings of the children with ALL who were between the ages of eight and
fourteen and who had no history of cancer were included in the study. The healthy sibling
control group allowed the researchers to control for potential co-varying factors such as socioeconomic status (SES), parent education, race/ethnicity, the effects of the family crisis, and
genetic propensity toward certain temperamental traits and abilities that impact cognitive and
educational performance. Table 1 provides a list of sibling pair demographic data (see Appendix
A for tables).
Recruitment
According to hospital records, 64 childhood cancer survivors met the criteria for this
study. A chart review of these 64 survivors was conducted and 24 families were identified that
had one or more siblings who also met the age and health criteria for this study. Potential
participants were contacted via first class mail and invited to participate in the study.
Approximately one week after receiving the letter, each family that had not already contacted the
researcher received a phone call from the researcher inquiring about their interest. Of the 24
families, 16 agreed to participate (participation rate of 67%). Four families did not respond to the
letter or to the follow-up call, and four more families refused participation. Of the 16 families
that agreed to participate, 14 families had a childhood cancer survivor who was male and two
who were female, thus gender could not be analyzed as a factor in this study. Families that
indicated interest were given opportunities to ask questions about the research during the phone
call. Upon verbal agreement to participate, an appointment for the testing sessions was
scheduled. Prior to the beginning of the testing session, the researcher gave the child (ages 9 to
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14) an assent form and the parent/guardian the study consent form to read and review. The
researchers verbally reviewed the assent form with 8-year-old participants as per hospital policy.
Measures
Intelligence.
Intelligence Composite-Wechsler Intelligence Scale for Children–Fourth Edition.
The Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; Wechsler,
2003) was used in this study as a benchmark of intellectual performance. For analysis, the
current study drew from procedures used by Kadan-Lottick et al. (2009), who used the Full Scale
Intelligence score. By using the Full Scale score on the WISC-IV, the intelligence quotient is
comprised of subtests that measure verbal comprehension, perceptual-reasoning, processing
speed, and working memory.
The WISC-IV is a clinical instrument for measuring the intellectual capacity of children.
The test comprises ten core subtests: Vocabulary, Similarities, Comprehension, Block Design,
Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and
Symbol Search. These subtests generate a Full Scale score (FSIQ), as well as four composite
indices: Verbal Comprehension (VCI), Perceptual Reasoning (PRI), Processing Speed (PSI), and
Working Memory (WMI). This instrument takes approximately one and a half hours for the child
to complete. Inter-rater-reliability coefficients (how much agreement there is in the test scoring
by different testers) for the Verbal Scale are .92 to .96 (average .95); Performance Scale are .89
to .94 (average .91); and Full-Scale are .94 to .97 (average .96). Criterion validity compares the
WISC-IV to previous versions of the WISC battery as well as other standardized cognitive
measures, such as the Stanford-Binet and the Kaufman Assessment Battery for Children. The
norm sample included 2,200 cases from across the nation, including 200 children in each of the
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11 age groups (ranging from 6 to 16 years). Norming data also included representative
percentages by socio-economic status, gender, and urban, suburban, and rural locations.
Verbal memory.
California Verbal Learning Test for Children.
The California Verbal Learning Test for Children (CVLT-C; Delis, Kramer, Kaplan, &
Ober, 1994) was used as the primary measure of verbal memory performance. To create a
memory composite score, this study drew from procedures in Anderson et al. (2009) and
Reddick et al. (2003) when using the CVLT-C. In both of these childhood cancer studies, the
researchers used the List A Total Trials 1-5 score as the general measure of overall verbal
memory performance. The CVLT-C assesses short-term and long-term memory in children ages
five to sixteen. A list of 15 words that can be organized into three categories (e.g., fruits,
clothing, and toys) is dictated to the child over five consecutive trials. The list of words is always
read in the same order. The child is asked to verbally recall the words immediately following
each trial. This instrument takes approximately 20 minutes for the child to complete, plus an
additional 20-minute delay to assess long-term free and cued recall. Internal consistency on the
test ranges from .81 to .91 across ages. Between trial consistency ranges from .84 to .91, and the
semantic categories reliability coefficient ranges from .64 to .80. Word consistency ranges from
.67 to .86. The CVLT shows moderate construct and content validity with the Wechsler
Intelligence Scale for Children - Revised Vocabulary subtest, with correlations ranging from .32
to .40. The norming sample consisted of 920 typically functioning children between the ages of
five and sixteen, and controlled for location within the United States, socio-economic status,
gender, and urban, suburban, and rural locations.
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Executive functioning.
The Rey-Osterrieth Complex Figure Test.
The Rey-Osterrieth Complex Figure Test (RCFT) (Osterrieth, 1944) was used as a
measure of visual spatial organization and planning. This study drew procedures from Campbell
et al. (2009) and Waber et al. (2007) for selection of subtests to examine planning and
organization skills. The rationale for this choice is rooted in Waber’s long history of use of the
RCFT with children with ALL, dating to the mid-1980s. Waber and Bernstein (1995) created the
developmental scoring system for the RCFT. The RCFT is a tool designed to measure a child’s
visual perceptual ability and organization of complex material by copying a figure and one
minute later drawing it from memory. The child is given five markers to use to complete the
copying task. The examiner asks the child to change markers upon request in order to better
assess the child’s organizational approach to the task. Based on Campbell et al. (2009) and
Waber et al.’s (2007) precedent, the current study used the RCFT Copy score, which scores the
quality of copying rather than the child’s organizational approach. Because of the complexity of
the figure, most children fail to reproduce it correctly. Production failure provides insight into the
preferred problem solving and organizational approach of the learner (Meyers & Myers, 1995).
Inter-rater reliability was randomly performed on 52 protocols with a reliability coefficient of .95
for the Copy-Organization score. Inter-rater reliability coefficient for the Style (copy) score was
.88). Raters’ ability to identify critical features ranged from .91 to .96 (Meyers & Meyers, 1995).
Test-retest reliability was not calculated due to clinical considerations that would make this
invalid (i.e., once a child has the experience of drawing the figure s/he is no longer naive to
drawing it). This test was normed on 450 children ages 6 to 14. The RCFT norming data used in
the current study was drawn from Myers & Meyers (1995) and consisted of 505 typically
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functioning children between the ages of 6-years-0-months and 17-years-11-months from the
Midwestern United States. In this norming sample the authors controlled for gender and
socioeconomic status.
Behavior Rating Inventory of Executive Functioning - Parent Form.
The Behavior Rating Inventory of Executive Function (BRIEF) (Gioia, Isquith, & Guy,
2001) was used in the current study as a measure of perceived executive functioning. A
composite score to measure perceived executive functioning was necessary in order to maximize
statistical power level and still analyze this domain. In order to create a composite score from the
parent rating measure, the current study used the procedures in Sullivan and Riccio (2006), in
which significant inter-correlations supported creating a Global Executive Composite from the
BRIEF Inhibit, Initiate, and Monitor subscales. It is important to note that the BRIEF is missing
data from two sibling pairs whose parents chose not to complete these forms. Therefore, analysis
was conducted with an n= 28 (14 sibling pair difference scores) instead of n = 32 (16 sibling
pair difference scores).
The BRIEF is a questionnaire for parents of school-aged children five-to-eighteen-years
old. This measure is normed on 1,419 parent and 740 teacher reports balanced for socioeconomic status, gender, and urban, suburban, and rural locations. The BRIEF has eight scales
that focus on different aspects of executive function (Inhibit, Shift, Emotional Control, Initiate,
Working Memory, Plan/Organize, Organization of Materials, and Monitor). Parents are asked to
respond to the 86 items on a 3-point Likert scale ranging from Never, Sometimes, to Always. This
instrument takes approximately 20 minutes to complete. The BRIEF’s internal consistency
coefficients range from .80 to .98 on the Parent Form, and test-retest correlations range from .76
to .88. Construct validity was determined by comparing the BRIEF to more general measures of
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behavior such as the ADHD Rating Scale-IV, the Child Behavior Checklist Parent and Teacher
Form, the Behavior Assessment System for Children, and the Connors’ Rating Scale. Through
correlations and factor analysis, the BRIEF was found to correlate strongly with measures of
general behavioral functioning, and to correlate less strongly with measures of emotional
functioning.
Attention.
Test of Variable Attention.
The TOVA was used in the current study to measure both inattentiveness and
impulsivity. The current study drew from procedures used in Aijaz et al. (2006). In their study of
medically fragile children, Aijaz et al. used attention composite scores to measure various
aspects of attentional performance. Similarly, this study used the TOVA omission and
commission scores to create two separate composite scores, one for inattention (omission) and
one for impulsivity (commission) to analyze attention. Composite scores were necessary to
maximize statistical power level for analysis of these domains. The composite scores were
created by combining the four quartile error scores separately for omission and commission
errors.
The TOVA is a measure of sustained attention and examines the participant’s errors of
omission (inattentiveness), commission (impulsivity), response speed, and variability of response
rate. The child completes the task on the computer and is told to click a finger-button switch
when a black box appears on top of the screen, and to not respond when the black box appears on
the bottom. This instrument takes approximately 25 minutes for the child to complete. The test
developers computed Pearson R correlations for all variables. Condition 1 (Quarters 1 and 2,
stimulus infrequent) reported correlations across quarters ranging from .69 to .92. Condition 2
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(Quarters 3 and 4, stimulus frequent) reported correlations ranging from .70 to .92. Cronbach
alpha, split-half, and Kuder-Richardson reliability coefficients, traditionally reported as a
measure of test consistency, are not appropriate for timed tasks such as the TOVA (Anastasi,
1988). Norming data consisted of 1,590 children and adults ranging from ages 4 to 80 from
across the United States. The majority of those tested were from either rural or suburban
Midwestern communities. The norming data controls for gender, but does not control for
socioeconomic status.
Processing speed.
Test of Variable Attention.
The Test of Variable Attention (TOVA; Greenberg, Kindschi, & Corman, 2000) was
used in the current study as a measure of processing speed. Response time is the amount of time
it took the subject to press the mouse button when the target was presented. The current study
created a composite Response Time score drawing from Aijaz et al. (2006), who combined the
four response time quartiles (Q1, Q2, Q3, and Q4) to create a composite score.
Academic achievement.
Wechsler Individual Achievement Test Second Edition.
The Wechsler Individual Achievement Test - Second Edition (WIAT-II; Wechsler, 2003)
was used in the current study to measure academic performance in reading and math. Reading
and math deficits for post therapy children with ALL are well documented (Armstrong et al.,
1999; Brown et al., 1998; Reddick et al., 2006). The current study created a composite score for
reading (Reading Comprehension and Pseudoword subtests), based on the inter-correlation for
these subtests reported by Wechsler (.48 - .65) on the Reading Comprehension and Pseudoword
subtests. The WIAT–II Reading Comprehension requires students to read several passages
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within a grade-appropriate item set and answer questions. Questions about the passages involve
detecting the main idea and supporting details, making inferences, and defining vocabulary. The
participants chose the best of four possible multiple-choice answers. The Pseudoword task
required decoding phonemic nonsense words.
The Math Reasoning task included counting, identifying shapes, and solving math word
problems. Participants were presented a series of math problems, both verbally and by visual
display, to assess their ability to reason mathematically. This test is not timed and participants
could use scrap paper if requested. This test takes approximately 40 minutes to administer.
Inter-rater reliability coefficients of WIAT-II subtests range from .71 to .99. Test-retest
reliability for subtests range from .81 to .99. Construct validity with the Math Reasoning subtest
and the WRAT3 Arithmetic Subtest is .77; WIAT-II Reading Comprehension subtest with
WRAT3 Reading is .73. Norming data consisted of a national sample of 2,950 participants
ranging in age from 4 to 19-years-11-months. Norming data also included variables such as
socio-economic status, gender, and urban, suburban, and rural locations.
Writing.
Three-Minute Writing Sample.
A three-minute writing sample was used to assess written expression abilities of the
participants. There is no known research regarding written expression and skills of post therapy
children with ALL. This task is not a nationally norm-referenced measure. The current study
utilized the three-minute writing task procedures described by Malecki and Jewell (2003) as
inter-correlations between total words written and the five other writing indices range from .56 to
.99. Total words written is a standard measure in response to intervention writing assessment
(Gansle, Noell, van der Heyden, Naquin, & Slider, 2002).
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The Three-Minute Writing task was scored using an original data set analyzed across
gender and grade level in the central United States (Malecki & Jewell, 2003). The participants in
that study were 946 first- through eighth-grade students from three schools in rural and suburban
northern Illinois. The sample consisted of 48% males and 51% females, but no other
demographic data was reported. The participants consisted of 133 (14.1%) first-graders, 200
(21.1%) second-graders, 168 (17.8%) third-graders, 192 (20.3%) fourth-graders, 127 (13.4%)
fifth-graders, 57 (6.0%) sixth-graders, 44 (4.7%) seventh graders, and 25 (2.6%) eighth-graders.
The original 3-minute writing task tested for Total Words Written, Words Spelled Correctly,
Correct Spelling Sequences, and Percentage of Words Spelled Correctly. Reliability and validity
data was not gathered. Studies find that three-minute writing samples correlate well with
standardized writing achievement scores (Amato & Watkins, 2011; Fewster & Macmillan,2002).
Procedures
Participants were asked to complete approximately four hours of testing consisting of
cognitive, academic, executive functioning, and information processing assessments across two
2-hour sessions on the same day (e.g., 10:00 am to 12:00 pm, and 1:30 pm to 3:30 pm).
Whenever possible, two participants were tested on the same day. This investigator was
responsible for administering all of the executive functioning, memory, and achievement
measures. A pediatric neuropsychologist administered all intelligence, attention, and processing
speed measures.
Testing was conducted at the Cure and Beyond Office (a cancer survivorship program)
within Hackensack University Medical Center. While the child was completing the evaluation,
the parent(s) were asked to complete two forms for further background information, along with
the BRIEF, which measures their perceptions of their child’s executive functioning abilities.
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Children with ALL and healthy siblings alternated between the two test administrators in the AM
or PM to control for time of day. The measures administered to the participants were evenly split
between AM and PM. One child in each family pair was administered the intelligence and
achievement measures in the AM, while the other child was administered the executive
functioning and information processing measures. The children switched measures for the PM
assessment session. In four instances families were unable to commit to completing testing in
one day and came back within two weeks to complete the testing. Within six weeks of
completing testing, the investigator and neuropsychologist scored tests and provided a brief
written report to the family describing their children’s functioning in each of the areas. Families
also were given the opportunity to meet with the researcher to discuss findings further upon
request. Upon completion of the testing, each participant received a $20.00 gift certificate to
Barnes and Noble or Toys R Us. In addition, each family was provided $20.00 to cover travel
expenses.
Confidentiality
The participants’ identities in this study remained confidential. Each participant was
identified by a number code system created by the investigator and employed after testing was
completed. This code was destroyed at the completion of this study and will not appear in any
publications or presentations of this material. The investigator reviewed participants’ health and
academic records. These records are maintained using the confidentiality rules set forth by
Hackensack University Medical Center and the Health Information Personal Privacy Act
(HIPPA) standards for medical, hospital, or psychiatric treatment records and are kept in a
locked cabinet in a locked office.
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Research Design and Statistical Analysis
The current study was designed to study the effects of high vs. low IT and TOT on the
cognitive, academic, and neuropsychological functioning of post therapy children with ALL,
using healthy siblings as the control. By using healthy siblings as the control, the data provide an
estimate of developmental capabilities while also controlling for the family experience and
demographics. Gender analysis was not possible, as only two of the 16 children with ALL were
female.
The current study assessed the neurocognitive late effects for high vs. low number of
intrathecal chemotherapy sessions. Typically, the more IT chemotherapy a patient receives, the
higher the likelihood for cognitive late effects (Espy et al. 2001; Heukrodt et al., 1988). Based on
findings in the research literature, participants were grouped either into the high IT group (20 or
more ITs) or the low IT group (19 or fewer ITs).
The current study also measured the effects of time off therapy (a variable often
associated with cognitive late effects) by creating a categorical time off therapy factor: each
participant was categorized as less than 5 years post treatment (TOT > 5 years), or 5 or more
years post treatment (TOT < 5 years). All of the current study’s children with ALL were two or
more years off therapy. The low TOT group’s ages ranged from 8 years – 5 months to 12 years –
6 months. The high TOT group’s ages ranged from 10 years – 4 months to 14 years – 9 months.
The design is in line with previous childhood cancer research showing that some cognitive
effects may present by two years off therapy, with even more late effects becoming apparent at
five or more years off therapy (Brown et al., 1998; Copeland et al., 1996; Espy et al., 2001;
Kingma et al., 2002; Nathan et al., 2007).
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All of the measures used in this study, with the exception of the writing task, are
nationally normed, age-based, standardized measures. The writing test is age-normed, but is
based on norming data from one school district in the Midwest. Due to limited sample size,
composite scores for measures were used when possible, rather than subtest analysis. When
composite scores were unavailable, either a combined subtest score or individual subtest scores
were used based on the practice in previous studies in the field of childhood ALL neurocognition
and childhood illness. While information was requested from teachers on student achievement,
there was a low response rate from teachers (4 out of the 16 children with ALL), and only 3 of
the 16 healthy siblings. This information was not used as the majority of the data was
incomplete.
Initially, the analysis plan was to conduct eight 2x2 ANOVAs and one MANOVA on
difference scores between children with ALL and healthy siblings. Inopportunely, for the 2x2
ANOVAs, one of the cells (<19 ITs and >5 years TOT) had a n = 0, as children treated over five
years ago typically received greater ITs (see Table 2: Scatter Plot). More recent protocols
prescribe fewer ITs, in an effort to reduce the number of neurocognitive late effects, while
keeping survivor levels at a high percentage. Therefore, the data were dealt with as two
independent factors, one studying the effects of IT and one studying the effects of TOT. Thus,
two analyses, with 10 one-tailed t-tests each, were conducted. For the t-tests, the factors were
low and high number of intrathecal chemotherapies (IT), and low and high time off therapy
(TOT). These t-tests were conducted on the sibling pair difference scores for each of the
measures administered. Difference scores permitted analysis of data in a way that maximized
power with a small sample size.
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A Cohen’s d score was also calculated to analyze effect size of high vs. low IT and high
vs. low TOT difference scores for each measure. The Cohen’s d measures the ratio of difference
between the means of two groups in relation to the size of their standard deviations (Sullivan &
Feinn,, 2012). Effect size can be useful in studies with small sample sizes, where there is a
greater likelihood of Type II error. According to Cohen (1992), typically 0.20 is considered a
small effect size, 0.50 is considered a moderate effect size, and 0.80 is considered a large effect
size. Unlike the Pearson r effect size, a Cohen’s d cannot account for a specific amount of
variance; it can only be used in the context of identifying a small, moderate, or large effect size.
Assessment of Violation of Assumptions
T-tests were conducted on the following domains using the measures indicated:
intelligence (WISC-IV full scale intelligence quotient), verbal memory (CVLT-C List A Trials
1-5 score), executive functioning (RCFT Copy score), executive functioning – parent report
(BRIEF Global Executive Composite score), processing speed (TOVA response time composite
score), inattention (TOVA omission composite score), impulsivity (TOVA commission
composite score), reading (WIAT-II Reading Comprehension and Pseudoword composite
score), math concepts (WIAT-II Math Reasoning score), and writing (three minute writing
sample – total words written score).
This study used sibling pair difference scores to compare ALL children to a proximal
representation (their siblings) of what their neurological function might have been without ALL
treatment. The t-tests allow one to test the significance of the difference between children treated
for ALL who have high or low numbers of intrathecal treatments and high or low time off
therapy, and their siblings. The study protected against Type I error by using the HolmesBonferroni a priori correction of the Alpha level to .005.
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Given the small sample size in this study, it is not surprising that testing of violation of
assumptions finds the study underpowered. A power analysis was conducted for an independent
sample t-test to determine a sufficient sample size using an alpha of 0.005, a power of 0.8, a
large effect size (d = 0.8), and one tail (Kock, 2015). Based on the aforementioned assumptions,
the desired sample size was 39 pairs.
Levene’s Tests for homogeneity of variance found homogeneity for eight of the ten IT
analyses and eight of the ten TOT analyses. For IT, the homogeneity assumption was violated for
inattention (p = .008) and impulsivity (p = .015). When analyzing TOT, the homogeneity
assumption was violated for inattention (p = .033) and Executive Functioning Parent Rating (p =
051).
A significant negative skew was found for: the high IT children with ALL on Reading
(-2.06) and Processing Speed (-1.13); the low IT children with ALL on Processing Speed (-1.06)
and Executive Functioning Copy (-1.03). For the high IT siblings, a negative skew was found on
Total Words Written (-1.16) and Executive Functioning Copy task (-1.21), and a positive skew
on Reading (1.12). Platykurtic kurtosis was found for: high IT children with ALL on Executive
Function Copy (-2.63) and the Executive Function Parent Rating (-2.23); the high IT siblings on
inattention (-2.01) and impulsivity (-2.29). Leptokurtic kurtosis was found on Reading for the
high IT children with ALL (4.59) and the high IT siblings (2.03).
A significant negative skew was found for: the high TOT children with ALL on Reading
(-1.39); the high TOT siblings on IQ (-1.12), Reading (-1.02), Processing Speed (-1.52), and
Verbal Memory (-1.40). Reading had a significant negative skew for low TOT siblings (-1.35).
Platykurtic kurtosis was found for the high TOT ALL children for Executive Function Copy
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(-2.44), as well as for the high TOT siblings for Processing Speed (-2.22). A leptokurtic kurtosis
was found for the high TOT children with ALL for Verbal Memory (2.25).
Given that this study was underpowered and that a number of the samples were not
normally distributed, the findings must be interpreted with caution. In addition, interpretation of
findings was complicated as all high IT children happened to also be high TOT, and all low IT
children happened to also be low TOT; but two children crossed groups because they were low
IT and High TOT. To assure the most conservative interpretation of findings, post hoc t-tests
deleted the two “mixed” sibling pairs. The resulting comparison of only high IT and high TOT
(n=7) vs. low IT and low TOT (n=7) sibling pairs, prevented the two mixed sibling pairs from
exerting a disproportionate effect on this study’s findings.
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Chapter 4: Results
Descriptive Statistics
This study used paired sibling difference scores on intelligence, achievement, and
neuropsychological measures to assess the effects of high and low number of intrathecal
chemotherapy treatments and high and low number of years off therapy on performance of
children who had been treated for ALL. Group descriptive statistics indicate that mean scores for
both the children with ALL and siblings are in the average ranges for the domains studied, with
the exception of below average inattention among siblings (see Table 3). Descriptive statistics
for the IT and TOT ALL groups are presented in Table 4. Descriptive statistics for the sibling IT
and TOT groups are presented in Table 5. Scores on the measures with significant t-test findings,
and large or moderate effect sizes, are found in Table 6 for children with ALL and Table 7 for
healthy siblings.
Sibling pair difference score groupings consisted of a high intrathecal (IT) group of >20
IT (n = 7), a low intrathecal group of <19 IT (n = 9), high time off therapy (TOT) group of >5
years (n = 9) and a low time off therapy group of <5 years (n = 7). The sibling pair difference
score analyses for high and low number of intrathecal chemotherapy groups (IT) are presented in
Table 8. The sibling pair difference score analyses for high and low time off therapy groups
(TOT) are presented in Table 9. Negative difference scores indicate that the children with ALL
performed more poorly than their healthy siblings. Positive difference scores indicate that the
children performed better than their healthy siblings.
Intelligence
Participants scored within the average to high average range on the Wechsler Intelligence
Scale for Children – Fourth Edition Full Scale IQ, with ten of the 16 children with ALL
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performing more poorly than their healthy sibling. The subscale group means and standard
deviations for children with ALL and their healthy siblings are presented in Table 10. The Full
Scale WISC-IV scores of individuals with ALL ranged from 87 to 116 (M = 103.25, SD = 8.73)
(see Table 11). Full Scale WISC-IV scores for the healthy siblings ranged from 85 to 121 (M =
107.31, SD = 8.70) (see Table 12).
Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being intelligence as operationalized by the WISC-IV Full Scale IQ. The Full Scale IQ
score combines the scores from all 10 subtests that assess intellectual functioning related to
verbal comprehension, perceptional reasoning, working memory, and processing speed. A
positive difference score indicates that the child with ALL performed better than his or her
healthy sibling, while a negative difference score indicates the child with ALL performed more
poorly than his or her healthy sibling. The t-test p-value for the factor IT was set at .005 (see
Table 8) and fell short of significance when applying the Holmes-Bonferroni Correction, t (14) =
1.798; p = .047, although the effect size was large (d = .89). The mean IQ difference score
between children with ALL who received high IT and their healthy siblings was approximately
minus nine points (M = -8.71, SD = 10.22), whereas the mean difference score between children
with ALL who received low IT and their healthy siblings was negligible (M = -0.44, SD = 8.20).
Mean IQ for children with ALL who received high IT was 102.00 (SD = 9.39), vs. 110.71 (SD =
6.34) for their healthy siblings.

46
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy high (TOT >5) and low (TOT <5), and the dependent variable being intelligence
as operationalized by the WISC-IV Full Scale IQ (see Table 9). The t-test indicated no
significant intelligence effects for the factor TOT, t (14) = .525, p = .304. The mean difference
score between high TOT children with ALL and their healthy siblings (M = -5.22, SD = 11.51),
versus the mean difference score between low TOT children with ALL and their healthy siblings
(M = -2.57, SD = 7.59), indicated that IQ scores of children with ALL who were off therapy for
varying periods of time were equivalent.
Reading Composite
The scores on the Wechsler Individual Achievement Test - Second Edition subtests
(WIAT-II) measuring reading comprehension and pseudoword reading ranged from low average
to high average. Children with ALL had reading composite scores ranging from 92 to 114 (M =
107.96, SD = 9.76). Scores for the healthy sibling group ranged from 92 to 123 (M = 108.96, SD
= 10.35). See Tables 6 and 7 for participants’ individual scores for Reading Composite.
Number of intrathecal chemotherapy (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being reading as operationalized by the Reading Composite score of the WIAT-II. The
reading composite score represents participants’ combined performance on the WIAT-II Reading
Comprehension and Pseudoword subtests. The t-test indicated a significant reading effect for the
factor IT, t (14) = 3.633, p <.001, and a large effect size (d=1.81) was noted (see Table 8) . The
mean difference score between children with ALL who received high IT was seven points lower
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than their healthy siblings (M = -7.36, SD = 6.54), while the mean difference score for the
children with ALL who received low IT was about four points higher than their siblings (M =
3.94, SD = 5.89) . Using the Holmes-Bonferroni Correction, these findings reach statistical
significance.
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being reading as
operationalized by the Reading Composite score of the WIAT-II. The reading composite score
represents subjects’ combined performance on the WIAT-II Reading Comprehension and
Pseudoword subtests. The t-test indicated no significant reading effects for the factor TOT, t (14)
= 2.077, p = .028, although the effect size was large (d=1.06) (see Table 9). The mean difference
score between children with ALL and their healthy siblings (M = -4.44, SD = 8.16) indicated that
children with ALL who were off therapy longer performed four points lower than their healthy
siblings on the reading composite measure. Low TOT children with ALL scored three points
above their healthy siblings (M = 3.43, SD = 6.56).
Math Reasoning
The scores on the Wechsler Individual Achievement Test - Second Edition (WIAT-II)
testing math reasoning ranged from low average to superior. The scores of children with ALL
ranged from 89 to 125 (M = 108.43, SD = 9.40) on math reasoning. Scores for the healthy sibling
group ranged from 85 to 132 (M = 109.12, SD = 12.70). See Table 6 (children with ALL) and
Table 7 (healthy siblings) for participants’ individual scores for math reasoning.
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Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being math reasoning as operationalized by the Math Reasoning Score of the WIAT-II.
The t-test indicated significant math reasoning effects for the factor IT, t (14) = 3.079, p = .004,
and a large effect size (d=1.61) was noted (see Table 8). The mean difference score between
children with ALL who received high IT was about nine points below their healthy siblings (M =
-8.85, SD = 6.04), while children with ALL who received low IT performed five points higher
than their healthy siblings (M = 5.22, SD = 11.46). Using the Holmes-Bonferroni Correction,
these findings reach statistical significance.
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being math
reasoning as operationalized by the Math Reasoning Score of the WIAT-II. The t-test was not
significant between the two groups for the factor TOT, t (14) = 2.791, p = .007, although the
effect size was large (d=1.30) (see Table 9). The high TOT mean difference score indicated that
children with ALL who were off therapy longer performed about seven points lower on the math
measure than their healthy siblings (M = -6.67, SD = 6.09). The mean difference score of the low
TOT children with ALL indicates they performed six points higher than their healthy siblings
(M = -6.43, SD = 12.83).
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Three-Minute Writing Sample
The scores for the three-minute writing task ranged from borderline to high average. The
scores of children with ALL ranged from 65 to 112 (M = 93.62, SD = 13.83) on the writing task.
Scores for the sibling group ranged from 72 to 120 (M = 96.83, SD = 19.93).
Number of Intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being writing as operationalized by the total words written. The t-test indicated no
significant writing effects for the factor IT, t (14) = .406, p =.345 (see Table 8).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being writing as
operationalized by the total words written. The t-test indicated no significant writing effects for
the factor TOT, t (14) = -.185, p = .527 (see Table 9).
Inattention
The Test of Variable Attention – Omission composite scores (inattention) ranged from
well below average to the average range for the participants in this study. The scores of children
with ALL ranged from 83 to 110 (M = 97.01, SD = 14.08). Scores for the healthy sibling group
ranged from well below average to the average range 41 to 105 (M = 83.31, SD = 22.87). See
Table 6 (children with ALL) and Table 7 (healthy siblings) for participants’ individual scores for
inattention.
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Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being inattention as operationalized by the TOVA – Omission composite score
(inattention). The t-test indicated no significant inattention effects for the factor IT, t (14) =
1.198, p = .125, although the effect size was moderate (d = .62) (see Table 8). The mean
difference score between children with ALL who received high IT and their healthy siblings
indicated that the siblings performed six points lower on this measure of inattention (M = 6.21,
SD = 16.06). The mean difference score between children with ALL who received low IT and
their healthy siblings was about 20 points lower for the siblings (M = 19.52, SD = 25.65).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being inattention
as operationalized by the TOVA– Omission composite score. The t-test indicated no significant
inattention effects for the factor TOT, t (14) = .707, p = .246 (see Table 9). The mean difference
score of high TOT children with ALL from their siblings indicated that children with ALL who
were off therapy longer performed over one standard deviation better than their healthy siblings
on the measure of inattention (M = 17.25, SD = 26.75). In contrast, the mean difference score of
low TOT children with ALL was nine points higher than their healthy siblings (M = 9.14, SD =
15.92).
Impulsivity
The Test of Variable Attention Commission composite scores, which tested impulsivity,
ranged from well below average to high average. The scores of children with ALL ranged from
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60 to 111 (M = 92.31, SD = 17.84). Scores for the healthy siblings ranged from 52 to 111 (M =
87.32, SD = 20.21). See Table 6 (children with ALL) and Table 7 (healthy siblings) for
participants’ individual scores for impulsivity.
Number of Intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being impulsivity as operationalized by the TOVA Commission composite score. The ttest indicated no significant impulsivity effects for the factor IT, t (14) = 1.304, p = .107,
although the effect size was moderate (d = .64) (see Table 8). The mean difference score between
children with ALL who received high IT and their healthy siblings indicated that they performed
similarly to their healthy siblings (M = -3.61, SD = 20.87). Low IT children with ALL
outperformed their healthy siblings by approximately 12 points (M = 11.67, SD = 24.86).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being
impulsivity as operationalized by the TOVA Commission composite score (impulsivity). The ttest indicated no significant impulsivity effects for the factor TOT, t (14) = -.415, p = .342 (see
Table 9). The mean difference score of the high TOT group was seven points (M = 7.22, SD =
28.20), and the mean difference score of the low TOT group was two points (M = 2.11, SD =
18.30), when compared to their healthy siblings.
Processing Speed
Scores for the Test of Variable Attention Response Time composite (TOVA) ranged from
well below average to the superior range. The scores of children with ALL ranged from 48 to
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121 (M = 95.37, SD = 24.07). Scores for the healthy siblings ranged from 56 to 117 (M = 92.40,
SD = 20.19).
Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being processing speed as operationalized by the TOVA. The t-test indicated no
significant processing speed differences for the factor IT, t (14) = .504, p = .311 (see Table 8).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
Time Off Therapy, high (TOT >5) and low (TOT <5), and the dependent variable being
processing speed as operationalized by the TOVA Response Time Score. The t-test indicated no
significant processing speed effects for the factor TOT, t (14) = .960, p =. 177 (see Table 9).
Verbal Memory
Participant’s scores ranged from below average to above average on the Combined List A
1-5 of the California Verbal Learning Test for Children (CVLT). The scores of children with
ALL ranged from 73 to 121 (M = 102.62, SD = 12.46). Scores for the healthy siblings ranged
from 76 to 121 (M = 99.86, SD = 12.66).
Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being verbal memory as operationalized by the CVLT combined List A 1-5. The t-test
indicated no significant verbal memory effects for the factor IT, t (14) = .046; p = .481) (see
Table 8).
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Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
Time Off Therapy, high (TOT >5) and low (TOT <5), the dependent variable being verbal
memory as operationalized by the CVLT Lists A 1-5. The t-test indicated no significant verbal
memory effects for the factor TOT, t (14) = -.018, p = .507 (see Table 9).
Executive Functioning
All but one subject’s scores were within average ranges on the Rey Osterrieth Complex
Figure Test (RCFT) Copy Measure. Scores of children with ALL ranged from 90 to 104 (M =
99.98, SD = 4.29). Scores for the healthy siblings ranged from 82 to 108 (M = 98.69, SD = 6.30).
Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being executive functioning as operationalized by the RCFT Initial copy score. The ttest indicated no significant executive function effects for the factor IT, t (14) = .582; p = .285
(see Table 8).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being Time
Off Therapy, high (TOT >5) and low (TOT <5), and the dependent variable being executive
functioning as operationalized by the RCFT Initial copy score. The t-test indicated no significant
executive functioning effects for the factor TOT, t (14) = .601, p = .279 (see Table 9).
Parent Perception of Executive Functioning
Participants’ scores ranged from below average to high average on the Behavioral Rating
Index of Executive Functioning - Global Executive Composite (BRIEF). The scores of children
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with ALL ranged from 84 to 130, (M = 100.32, SD = 17.10). Scores for the siblings ranged from
84 to 133, (M = 103, SD = 17.20).
Number of intrathecal chemotherapies (ITs).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent
variable being parent perspective of executive functioning as operationalized by the BRIEF Global Executive Function Composite, which consists of the BRIEF Inhibit, Initiate, and
Monitor scores. The t-test for the factor IT indicated no significant executive functioning effects
based on parent perspectives, t (12) = .392; p = .278 (see Table 8).
Time off therapy (TOT).
A one-tailed t-test on sibling pair difference scores was conducted with the factor being
Time Off Therapy, high (TOT >5) and low (TOT <5), and the dependent vaariable being parent
perspective of executive functioning as operationalized by the BRIEF. The t-test indicated no
significant executive functioning effects of TOT, based on parent perspective, t (12) = .370, p =
.337 (see Table 9).
Post Hoc Analysis
There are many limitations that threaten both the internal and external validity of this
study. Many of the issues stem from the small sample size. Despite best efforts to obtain a larger
cohort, the sample size issue that is common with single site pediatric cancer studies occurred in
this study as well. Therefore, interpretation of the findings need to be cautious and conservative.
Moreover, interpretation of findings was hampered due to the artificial division of
participants into high and low groups. To help understand the findings a post hoc correlation
analysis examined the relationship between number of intrathecal chemotherapies and the
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amount of time off therapy for the children with ALL. Results indicated a positive relationship
between IT and TOT r(16) = .72.
In addition it was noted that seven participants in the high IT group also were in the high
TOT group, and seven in the low IT group also were in the low TOT group; this meant that data
for these students were identical when analyzing high vs. low IT or TOT. In contrast, the
remaining two participants contributed unique variance in the analyses because they were
“mixed”: in the low IT group but high TOT, These two mixed children may have
disproportionately affected the findings as either their IT or TOT was unlike that of their other
group members. It could be argued that the analysis might have been done best by excluding
these two families. In this case, the groups in all domains would be n = 7 for high IT and high
TOT, and n = 7 for low IT and low TOT.
To explore this point, post hoc analyses was conducted, without the two mixed pairs, for
all domains that had a significant finding or moderate to large effect size in the original analyses.
As in the original analysis, the t-test (n = 14) found significantly poorer reading composite (p =
.005) and large effect size (d = 1.65) for the high IT (and high TOT) group, than for the low IT
(and low TOT) group, when compared with their healthy siblings (p = .005). Unlike the original
analysis, the math reasoning effect for children with ALL missed significance (p = .007), though
the effect size remained large (d = 1.52). The original analysis reported a large effect size for
FSIQ, which in the post hoc analysis became a moderate effect size (d = .68). The moderate
effect sizes for inattention and impulsivity in the initial analysis did not hold up in the post hoc
analyses. Given these post hoc results, a conservative and cautious approach to interpretation of
the results is warranted.
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Summary
This study examined the intellectual, academic, and neuropsychological outcomes of
ALL treatment using a sibling-controlled design. Overall, the post therapy children with ALL
and their healthy siblings performed in the average range for all the domains studied. The only
exception was for both inattention and impulsivity, where the healthy siblings in the low IT and
high TOT groups scored below average.
Despite the overall average performance of the children with ALL, children who had
received high numbers of intrathecal chemotherapy treatments had significantly lower reading
composite and math performance than the low IT ALL group, relative to their healthy siblings.
The children with ALL in the high IT and high TOT groups demonstrated a large effect size for
both the reading composite and math reasoning domains. Intelligence quotient showed a large
effect size for high IT children with ALL, who scored lower than low IT children with ALL,
when compared to their healthy siblings. Moderate effect size for inattention and impulsivity also
related to the factor number of ITs, where low IT children with ALL outperformed their healthy
siblings. Given that several of these findings did not hold up in the post hoc analyses, they
should be interpreted with caution.
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Chapter 5: Discussion
Major Findings
The current study’s findings replicate prior research demonstrating delays in IQ, reading,
and math achievement for children who had been treated for ALL, although their performance
was in the average range. The study supports findings (Brown et al., 1996; Brown et al., 1998;
Espy et al., 2001; Lyer et al., 2016; Peterson et al., 2008; Reddick et al., 2006) that the relative
delay experienced by children with ALL in these areas is related to high IT. There also is
evidence in this study that the relative delay on reading composite and math reasoning is
influenced by high TOT. In this study, low IT (19 or fewer ITs) and low TOT (under 5 years off
therapy) were not related to any harmful effects on the participants’ cognitive, academic, or
neuropsychological development.
In summary, when compared to their siblings, children who received 20 or more ITs
performed poorer on intelligence, reading, and math measures than those who received 19 or
fewer intrathecal treatments. In addition those with five or more years off therapy were more
discrepant from their siblings in reading and math reasoning than children with ALL who were
off therapy fewer than five years. Because there was no baseline data available, it is impossible
to know if the losses experienced by children with ALL are minor or major losses. These
findings suggest that future research should explore in greater depth the particular elements of
intelligence, reading, and math that are affected by ALL treatment, in order to take preventive
and remedial action. Despite treatment effects noted in this study, it is heartening that, after two
and a half years of therapy that includes systemic chemotherapy, intrathecal chemotherapy, and a
host of other treatments, post therapy children with ALL generally performed at expected levels
for their ages on the study’s measures.
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This study did not replicate findings of prior research that showed weaknesses in verbal
memory, processing speed, attention, and executive functioning in children who had been treated
for ALL. In addition, no weaknesses were found on factors that have seldom been explored in
the ALL literature: writing prose, parent rating of executive functioning, and the role of
impulsivity in poor attention.
The findings of this study suggest that, where sample size is low, sibling difference
scores might be a valuable method of analyzing the effects of treatment on post therapy children
with ALL, and possibly other types of rare childhood medical conditions. Analyzing difference
scores, one factor at a time, provides an alternative to the ANOVA when cell size is small, as is
common in single site studies.
The findings of this study also suggest that comparing the number of IT chemotherapies,
and how these affect intelligence, achievement, and neuropsychological outcomes, is valuable in
studying long term effects of ALL treatment where matching of treatment protocols is not
possible. The current study adopted Ashford et al.’s (2010) and Pui et al.’s (2003) method of
using number of ITs to study the impact of high vs. low IT on children with ALL.
Only six known studies (in addition to the current study) have used sibling control groups
(Jansen et al., 2008; Kaemingk et al., 2004; Mitby et al., 2003; Reddick et al., 2006; Reeves et
al., 2007; Rodgers et al., 2003). Of these studies, Jansen et al., Reddick et al., and Reeves et al.
used a neurocognitive battery similar to that in the current study. The use of healthy sibling
controls allowed this study to control for the family’s cancer experience, family genetics, and for
demographics, such as SES and parental education level. It could not control, however, for age,
gender and undiagnosed medical or psychosocial conditions. Due to this and other
methodological issues in this study, any conclusions must be interpreted cautiously.
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Domain Specific Findings
Research has indicated that general IQ may be affected by higher cumulative doses of IT
chemotherapy (Kingma et al., 2002; Ochs et al., 1991; Reddick et al., 2006). The current study
found a similar impact on intellectual functioning when receiving 20 or more ITs. The current
study did not find any effect on IQ when analyzing the number of years off therapy.
Recent studies have found moderate reading decoding delays among children who have
been treated for ALL (Campbell et al., 2007; Peterson et al., 2008; Reddick et al., 2006; Spiegler
et al., 2006). Some studies have found reading comprehension delays as well, while others have
not (Brown et al., 1998; Campbell et al., 2007; Espy et al., 2001; Waber et al., 2007). The
findings from the current study support previous research demonstrating that a relative reading
weakness, when compared to their healthy siblings, is not unusual for children with ALL who
were treated with high IT and were five or more years off therapy. Perusal of the group means
indicated that pseudoword reading was comparable across all groups, and that the significant
findings for reading composite likely were due to weaker reading comprehension in high IT
children with ALL; these children scored 12 points lower on the Reading Comprehension subtest
than their healthy siblings. Similarly, the high TOT children with ALL underperformed their
healthy siblings by about eight points. Low IT and low TOT children with ALL performed on
both tasks very much like their healthy siblings. Future research needs to explore which of these
aspects of reading skill are most at risk, as both are critical to reading success.
Similar to reading, the majority of studies of math achievement have shown math
calculation delays in children treated for ALL (Brown et al., 1996; Carey et al., 2008; Espy et al.,
2001; Kaemingk et al., 2004; Reddick et al., 2006; Waber et al., 2007). The current study is one
of only a few that utilized math reasoning rather than math calculations in the assessment battery.
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The analyses demonstrated a relative weakness in math reasoning, when compared to their
healthy siblings, for both the high IT and high TOT groups; children with ALL scored
approximately one-half SD below their healthy siblings in both cases. In contrast, the low IT and
low TOT ALL groups performed somewhat stronger than their siblings. It is suggested that
further research consider a mathematics-specific study that compares math calculation versus
conceptual math ability, relative to number of ITs and time off therapy for survivors of childhood
ALL.
There were unexpected moderate effect size findings for inattention and impulsivity in
the original analyses, with healthy siblings scoring worse than the children with ALL. When the
post hoc analysis was conducted, however, these findings changed to a small effect size. The
effect of the two mixed families that switched in the analysis between the high and low groups,
exemplifies the concern that with a small sample size even two family pairs can
disproportionately affect findings. Table 13 illustrates the number of times that individual
families showed large variability in performance between the two siblings, again calling for a
conservative approach to conclusions drawn from this study. In addition to the above concerns,
it should be noted that some of the sibling data in this small N study was not normal, therefore
complicating interpretation.
Despite caution in interpreting this study’s findings, the question of how the cancer
experience effects siblings remains. Reddick et al. (2006), one of three known studies of ALL
chemotherapy effects to use a matched sibling control group to study attention, found attentional
issues with the healthy siblings.
The researcher contacted Dr. Reddick from St. Jude’s Hospital to request unpublished
data from his study regarding healthy sibling attention. In an email correspondence, Dr. Reddick
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(2/18/2010) shared unpublished healthy sibling data, which demonstrated attention issues on the
Conner’s Continuous Performance Test (CPT) (see Table 14). According to the Connors CPT,
T-scores in the low 60s are mildly atypical and T-scores of 70 or higher are considered markedly
atypical. Reddick et al. reported extremely atypical omission scores for sibling controls on the
Conner’s CPT (t = 80.75 + 19.199), while performance of children with ALL was “at risk” (t =
62.9 + 8.7).
A review of Sharpe and Rossiter’s (2002) meta-analysis of 51 studies across different
childhood medical conditions found that cognitive development scores were lower for siblings
who had a brother or sister with a chronic medical condition than for siblings who had healthy
brothers or sisters. Research on siblings of children with cancer almost always focuses on social
or emotional aspects of having a sibling with a life-threatening illness (e.g., post-traumatic stress
disorder symptoms) and not on cognitive consequences (Alderfer, Labay, & Kazak, 2003;
Campbell et al., 2009; Kazak et al., 2004). For example, Alderfer et al. (2003) found that 49% of
siblings exhibited mild post-traumatic stress disorders (PTSD), and an additional 32% exhibited
moderate to severe levels of PTSD. This data suggests that a sizable percentage of siblings of
childhood ALL survivors may be at risk for experiencing emotional and/or other disorders
related to the shared childhood cancer experience and that this should continue to be explored.
Limitations
The small, self- selected convenience sample, coupled with the large number of
dependent variables measured and the artificial grouping into high or low IT and TOT groups
caused analysis concerns in this study. Control for sex, age, SES, age at diagnosis of ALL,
treatment protocol, and other factors in this study was not possible. Moreover, this was an
underpowered study that also had issues of normality on some of the measures. Despite findings
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that replicate other, (e.g., Brown et al., 1996, Brown et al., 1998; Kaemingk et al., 2004), this
study’s results need to be interpreted cautiously due to the many methodological constraints.
As is the case with many single-site research studies of children with cancer, the small
sample size left the current study vulnerable to Type II error: failing to find significance due to
limits with power (Campbell et al. 2007). Sample size required this study to utilize composite
scores, which then limited the ability to distinguish patterns across the composites’ subtests. For
example, although reading composite results were significant, performance on the pseudoword
(decoding) task could not be compared statistically with reading comprehension performance.
The current study’s limited sample size prevented a more processing-focused approach to
understanding intelligence, achievement, and neuropsychological functioning with this
population of learners.
Unfortunately, the present study had only two female participants with ALL. Numerous
studies have found females with ALL to be more susceptible to cognitive late effects of
treatment (Brown et al., 1998; Butler et al., 2002; Mulhern et al., 2004), but this couldn’t be
explored further in this study.
Another limitation is that this study focused on math reasoning only. Most previous
research has focused on math calculation. Studies with post therapy children with ALL that
focus on both math concepts and math calculations would be essential to better understand the
impact of the cancer experience on math skills.
Design issues are common in this field of work, as so few children are diagnosed with
childhood cancer (Moore, 2005). Children at a single hospital will typically be treated on
different protocols and a number of variables will impact the amount of treatment they receive
(e.g., age, weight, gender, disease progression at time of diagnosis). All of these factors influence
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the treatment regimen and ultimately potential outcomes. For example, all participants with ALL
in the current study received methotrexate via IT, which puts them into a higher risk category for
late effects than had non-methotrexate protocols been followed. However, the sample size
prevented analysis of the data by age, chemotherapy protocol, and the other relevant variables
mentioned above.
Grouping participants into high and low IT groups also brings up the issue of how much
the significant findings for high vs. low IT were related to the anesthesia necessary to administer
treatment, rather than to the chemotherapy itself. At each IT treatment, the patient with ALL
receives general anesthesia. Although the effects of anesthesia in children are not well known,
Wilder et al. (2009) found that when children under the age of four are exposed to multiple
anesthetics (two or more), there is a statistically significant increase in learning disabilities later
in life. Similarly, Flick et al. (2011) found that multiple anesthetics increased the likelihood for
learning disabilities, even when the analysis ruled out confounding health related issues that may
themselves negatively impact learning. Ing et al. (2012) found that children under the age of
three who were exposed to anesthesia were more likely than their healthy peers to experience
significant delays in receptive language, expressive language, and cognition. This raises the
question of whether some portion of detrimental effects typically experienced by children with
ALL may be due to factors related not just to the intrathecal treatment but to other aspects of the
treatment experience as well, such as anesthesia effects.
Another factor this study was unable to account for was the effect of direct instructional
time and number of days absent from school, both of which could affect the performance of
children with ALL. Also, considering this was a single-site study at a treating institution with a
robust educational intervention program, it is unclear how these educational services influenced
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the outcome of this study. It is estimated that approximately 60 of the 230 children’s hospitals in
the U.S. have some level of dedicated educational support staff, making this treatment center
somewhat unusual with its high level of support (two full-time educational liaisons). Much still
needs to be learned about the impact of these programs, and whether participants, such as in this
study, experience fewer academic and cognitive late effects of treatment due to the intensive
educational and emotional support they receive during- and post-treatment.
Seven children with ALL (44%) in this study took advantage of hospital educational
outreach services, and nine of the children with (56%) agreed to have the hospital set up a 504
Plan or Individual Educational Program (IEP) while on treatment. Students with 504 Plans
received extra time on tests, extra time passing in the hall, and other accommodations, such as
note-takers when absent from school. Students with IEPs were given the same accommodations,
but also benefitted from additional direct instruction by educators at home or in the hospital. This
support may have mitigated the development of more serious delays. Unfortunately, a record
review did not reveal any further information that could be used to interpret the relative strengths
and weaknesses of the children treated for ALL.
Implications of Findings
This study has five important findings to contribute to the study of effects of treatments
on children with ALL:
1) In general, post therapy children with ALL are performing within average ranges in
every domain assessed, which implies that treatment protocols are causing less harm in the
realms of cognition, learning, and information processing than in the past. In fact, the average
performance of children with ALL in the low IT group surpassed their healthy siblings in reading
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composite, math reasoning, attention measures, processing speed, verbal memory, and executive
functioning (copying task).
2) This study’s findings replicated neurocognitive relative weaknesses for post therapy
children with ALL who received high IT on intelligence, reading composite, and mathematics
reasoning tasks.
3) This study explored the impact of a five-year time off therapy split to investigate if and
when declines in skills such as reading and math reasoning become evident. The results from this
study show that late effects in reading and math reasoning are particularly problematic five or
more years off therapy.
4) This study demonstrated that number of ITs may be a possible substitute when
cumulative dosage information is not a practical option, due to small sample size and multiple
treatment protocols.
5) This study utilized sibling difference scores as the data for analysis when studying
childhood ALL. The use of difference scores proved promising for maximizing power, given the
small sample size.
Continued study of the cognitive, academic, and neuropsychological effects of childhood
ALL treatments is important in order to identify and find ways to mitigate delays that become
apparent over time. With more knowledge about the treatment factors that are particularly
deleterious, treatment protocols can be modified and educational interventions introduced to
prevent predicted neurocognitive weaknesses.
Suggestions for Future Research
The findings of this study suggest there is still much to learn and understand about the
cognitive, academic, and neuropsychological characteristics and needs of children treated for
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acute lymphocytic leukemia. The continued participation of healthy sibling cohorts in
neurocognitive studies also is useful in shedding light on the needs of healthy siblings who have
lived through the cancer experience. Of course, the use of a healthy sibling has its limitations as
each sibling and each home experience is unique. Therefore, in addition to healthy sibling
groups, researchers should continue to use other comparison groups of children with chronic
conditions or survivors of childhood cancers that do not require cognitively threatening therapy.
These controls allow the researcher to differentiate the psychosocial issues, as well as treatment
protocol and disease effects, on learning and development. The need for larger sample sizes
when possible is evident.
When possible, future researchers should consider gathering samples from multiple
childhood cancer treatment institutions in order to obtain an adequate number of subjects to
control for the variables that could not be controlled in this study. When small sample sizes are
unavoidable, it is recommended that researchers choose a more narrow focus of study so that
specific areas of cognitive functioning may be evaluated in more depth. This study suggests that
the many aspects of reading decoding, comprehension, math calculation and math reasoning be
explored in depth by using diagnostic assessment batteries. The more researchers can discover
about the weaknesses contributing to academic delays, the more able educators will be to design
interventions that target the weaknesses and accelerate success. When there are no diagnostic
batteries to measure a certain skill, it is recommended that multiple measures of the same
construct be administered (e.g., executive functioning, attention) to tap its multiple components
to the fullest extent possible. In addition, more research is needed to better understand what
impact there is on affective functioning such as resilience and risk taking, and how these factors
impact the academic functioning of children with ALL. Finally, while it is difficult to do,
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research in the field would be clearer if baseline data could be collected at the time of ALL
diagnosis, or as soon after treatment begins as is practical.
Given recent MRI results pointing to structural brain differences associated with ALL
treatment, future childhood ALL research may find it useful to use FMRI to compare brain
activation during specific tasks. Studies also could consider including in the assessment battery a
computerized continuous processing test (CPT) to measure attentional issues.
While a high amount of IT chemotherapy is typically considered a negative predictor in reading
and math areas, so is more time off therapy. In addition to accounting for the number of ITs and
cumulative dosage that a child receives, future studies should continue to explore the role of
TOT, which suggests that relatively negative effects become more apparent with time, especially
five or more years post-treatment. What remains unexplored is if the relationship between
longer time off therapy and difficulty in learning tasks relates to the more challenging academic
expectations in the upper elementary grades or to the loss of instructional time when basic skills
were being developed. Given the high inter-correlation between IT and TOT among post therapy
children with ALL, future research should attempt to tease out how much of the treatment effects
reported in the literature are accounted for by IT, and how much by the more difficult school
curriculum as TOT increases. Specifically, studies with larger sample sizes could examine the
interaction between time off therapy and ITs in relation to task demands that get harder. In larger
studies, control for the age when the child became ill also is recommended.
The cancer experience stretches a family’s time, emotional, and financial resources
(Labay & Walco, 2004; Steinglass, 1998). Prior research has documented the social-emotional
effect of cancer treatment on patients, and recent research has begun to focus on long-term
psychosocial effects on healthy siblings without cancer, primarily in the form of PTSD issues.
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Alderfer et al. (2003; 2010), Campbell et al. (2009), Kazak et al. (2004), and Long, Marsland,
and Alderfer (2013) have found that the cancer experience has a considerable emotional and
social toll on the healthy siblings as well as the child with ALL. This body of work emphasizes
the need to provide increased support early on, not only to children with cancer, but also to their
families in general, and to the siblings specifically. The need to more systematically measure
whether early psychoeducational support helps to minimize relatively negative effects on the
healthy siblings is very important.
Future studies at a national level also should compare the outcomes from treating
hospitals that have educational services for children with ALL vs. those that do not. Canada
recently moved to standardizing psychosocial care at all 17 of the pediatric cancer centers
throughout the country. Therefore, if a child in Canada is diagnosed with cancer, the child will
receive the same level of educational service regardless of SES, geography, or treating
institution. This includes standardizing the educational supports childhood cancer patients
receive while on treatment and after treatment is completed. This allows Canada to conduct
national studies focused on various aspects of psychosocial and educational care, including
educational and cognitive effects of childhood cancers. This type of national study is not possible
in the U.S. at this time.
Peterson et al. (2008) concluded that a national standardized neuropsychological battery
needs to be created and implemented across studies of ALL outcomes in hopes of being able to
better track outcomes and impediments in the educational experience of children with ALL. This
in turn would allow educators to be more proactive regarding the learning needs of children with
ALL, even after treatment has terminated. There is a move among hospital-based educators in
the U.S. to begin to address these concerns (Irwin & Elam, 2011).
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The current study indicates that high numbers of IT treatments appear to be problematic
for reading and mathematics skills, and affect intellectual functioning. In addition, late effects of
ALL treatment are more evident five years or more off therapy, than fewer years off therapy.
Much more research needs to be conducted on the issues discussed above. Fortunately for
children with ALL, lower number of IT treatments continues to be the trend in treating the
disease, which seems to result in fewer decrements in achievement. Moreover, the TOT literature
implies the need to take preventive educational measures, in the hopes of stemming predictable
late effects of treatment.
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Table 1
Sibling Pair Demographic Data

Sibling
Pair No.

Age at
Time of
Testing

Number
of ITs

Family 1
Survivor
Sibling

10-7
12-10

19

Family 2
Survivor
Sibling

9-4
10-10

Family 3
Survivor
Sibling

10-9
13-3

Family 4
Survivor
Sibling

11-0
13-11

Family 5
Survivor
Sibling

Time Off Therapy
Years -Months-Days

Gender

SES

Race

4 -10 -19

Male
Male

Upper
Middle

White

3 - 3-22

Male
Female

Middle

White

4 - 2 -27

Male
Female

Upper
Middle

White

16

4 - 1 – 28

Male
Female

Upper
Middle

White

10-7
8-5

18

3 - 10 – 16

Male
Male

Upper
Middle

White

Family 6
Survivor
Sibling

12-6
10-8

16

2 - 10 - 11

Male
Female

Upper
Middle

White

Family 7
Survivor
Sibling

11-7
8-0

16

2 -9 -8

Male
Female

Middle

White

Family 8
Survivor
Sibling

11-10
13-3

19

5 - 9 - 0

Male
Male

Lower
Middle

White

16

15
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Sibling
Pair No.

Age at
Time of
Testing

Number
of ITs

Time Off Therapy
Years -Months-Days

Gender

SES

Race

Family 9
Survivor
Sibling

10-4
8-0

17

7 - 0 - 21

Male
Female

Lower
Middle

White

Family 10
Survivor
Sibling

14-9
11-9

20

7 - 11 – 3

Male
Female

Upper
Middle

White

Family 11
Survivor
Sibling

12-8
11-0

22

6 - 1 – 25

Female
Male

Middle

Hispanic

Family 12
Survivor
Sibling

13-9
12-0

22

6-– 9 - 19

Male
Female

Middle

White

Family 13
Survivor
Sibling

14-0
12-2

20

7-7–0

Male
Female

Upper
Middle

White

Family 14
Survivor
Sibling

12-7
11-0

22

6 - 1 – 15

Male
Female

Upper
Middle

White

Family 15
Survivor
Sibling

14-4
11-7

22

6 - 1 – 26

Female
Male

Low
Middle

White

12-6
14-7

21

8 – 1 - 20

Male
Male

Middle

White

Family 16
Survivor
Sibling

Note. SES = Socioeconomic Status; ITs = Number of Intrathecal chemotherapies.
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Table 2
Scatter Plot of Participant IT and TOT Groups

Groups By Number of ITs and TOT
23

High IT & Low TOT (n = 0)

High IT & High TOT (n = 7)
a

22

Number of ITs

21

20

19

18

17

16

15

Low IT & Low TOT (n = 7)

14
900

1400

Low IT & High TOT (n = 2)
1900

2400

2900

Time Off Therapy In Days

Note. ITs = number of intrathecal chemotherapies; TOT=time off therapy; a = 3 subject data
points (all completed therapy within three days of each other).
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Table 3
Descriptive Statistics for Children with ALL and Healthy Sibling Groups
Children with ALL
n = 16

Siblings
n = 16

Domain
& Measure

M (SD)

M (SD)

Intelligence Quotient:
WISC-IV Full Scale IQ

103.25(8.73)

107.31(8.70)

Reading Composite:
WIAT-II

107.96(9.76)

108.96(10.35)

Mathematics:
Math Reasoning

108.43(9.40)

109.12(12.70)

Writing: Three-Minute
Writing Sample

93.62(13.83)

96.83(19.93)

Inattention:
TOVA Omission

97.01(14.08)

83.31(22.87)

Impulsivity:
TOVA Commission

92.31(17.84)

87.32(20.21)

Processing Speed: TOVA
Response Time Composite

95.37(24.07)

92.40(20.19)

Verbal Memory:
CVLT List A 1-5

102.62(12.46)

99.86(12.66)

Executive Function:
RCFT – Copy

99.98(4.29)

98.69(6.30)

Executive Function:
BRIEF – Global
Executive Composite

100.32(17.10)
n=14

103.00(17.20)
n=14

Note. M = mean; SD = standard deviation; n = sample size; WISC-IV = Wechsler Intelligence
Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual
Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT = California
Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating
Inventory of Executive Functioning.
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Table 4
Descriptive Statistics for High/Low IT and High/Low TOT Groups of Post Treatment for
Children with ALL
High IT
(>20)
n=7

Low IT
(<19)
n=9

High TOT
(>5 years)
n=9

Low TOT
(<5 years)
n=7

Domain
& Measure

M (SD)

M (SD)

M (SD)

M (SD)

Intelligence Quotient:
WISC-IV Full Scale IQ

102.00(9.39)

104.22(8.61)

101.66(10.59)

105.28(5.67)

Reading Composite:
WIAT-II

107.85(8.92)

108.05(6.72)

107.00(6.76)

Mathematics:
Math Reasoning

106.57(10.32)

109.44(8.96)

105.33(9.60)

112.42(8.05)

Writing: Three-Minute
Writing Sample

95.81(16.56)

93.07(16.11)

95.04(10.08)

91.79(18.31)

Inattention:
TOVA Omission

95.71(9.25)

98.02(9.15)

98.41(9.70)

95.21(8.28)

Impulsivity:
TOVA Commission

88.92(18.42)

94.94(12.03)

91.55(17.40)

93.28(12.18)

Processing Speed: TOVA
Response Time Composite

97.25(24.49)

93.91(22.80)

100.22(22.02)

89.14(23.93)

Verbal Memory:
CVLT List A 1-5

105.28(8.15)

101.44(15.29)

102.88(13.71)

103.42(11.74)

Executive Function:
RCFT – Copy

101.46(1.83)

98.82(5.35)

101.51(1.89)

98.01(5.77)

106.99(28.85)

95.77(22.98)

109.04(20.67)

(n = 6)

(n = 8)

(n = 8)

Executive Function:
BRIEF – Global
Executive Composite

109.21(9.33)

92.12(22.18)

(n = 6)
Note. IT = Intrathecal chemotherapies; TOT = Time off therapy; M = mean; SD = standard
deviation; n = sample size; WISC-IV = Wechsler Intelligence Scale for Children - Fourth
Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual Achievement Test - Second
Addition; TOVA = Test of Variable Attention; CVLT = California Verbal Learning Test; RCFT
= Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating Inventory of Executive
Functioning.

76
Table 5
Descriptive Statistics for High/Low IT and High/Low TOT Groups of Healthy Siblings
High IT
(>20)
n=7

Low IT
(<19)
n=9

High TOT
(>5 years)
n=9

Low TOT
(<5 years)
n=7

Domain &
Measure

M (SD)

M (SD)

M (SD)

M (SD)

Intelligence Quotient:
WISC-IV Full Scale IQ

110.71(6.34)

104.66(9.68)

106.88(10.28)

107.85(6.89)

Reading Composite:
WIAT-II

115.21(4.09)

104.11(9.80)

111.44(8.46)

105.78(10.42)

Mathematics:
Math Reasoning

115.42(9.08)

104.22(13.35)

112.00(10.45)

105.99(15.13)

Writing: Three-Minute
Writing Sample

94.33(11.43)

97.63(12.52)

97.60(14.78)

95.85(13.86)

Inattention:
TOVA Omission

89.50(14.12)

78.50(20.21)

81.16(21.29)

86.07(14.26)

92.53(8.36)

83.27(21.81)

84.33(17.93)

91.17(17.34)

91.25(24.99)

93.30(11.25)

92.86(22.02)

91.82(12.20)

101.85(8.82)

98.44(15.37)

98.77(9.78)

101.42(16.38)

100.94(3.73)

96.95(7.55)

100.51(5.47)

96.36(7.01)

106.83(14.85)

100.12(15.03)

109.85(15.74)

96.14(10.76)

(n = 6)

(n = 8)

(n = 8)

(n = 6)

Impulsivity:
TOVA Commission
Processing Speed:
TOVA Response Time
Composite
Verbal Memory:
CVLT List A 1-5
Executive Function:
RCFT – Copy
Executive Function:
BRIEF – Global
Executive Composite

Note. IT = Intrathecal chemotherapies; TOT = Time off therapy; M = mean; SD = standard
deviation; n = sample size; WISC-IV = Wechsler Intelligence Scale for Children - Fourth
Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual Achievement Test - Second
Addition; TOVA = Test of Variable Attention; CVLT = California Verbal Learning Test; RCFT
= Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating Inventory of Executive
Functioning.

77
Table 6
Children with ALL: Mean Scores on Significant, Large, and Medium Effect Size Measures
Family No.:
(Groups)

FSIQ

1
(Low IT Low TOT)

105

2
(High IT High TOT)

112

3
(Low IT High TOT)

Reading
Composite

Math
Reasoning

Inattention

Impulsivity

100

97

97

112

113

83

94

87

98

96

110

60

4
(High IT High TOT)

98

112

103

97

101

5
(Low IT Low TOT)

108

113.5

125

96

108

6
(High IT High TOT)

116

113

123

103

94

7
(Low IT High TOT)

106

110

106

106

91

8
(Low IT Low TOT)

105

116

109

84

81

9
(Low IT Low TOT)

105

112.5

111

100

98

10
(High IT High TOT)

92

106.5

104

101

70

11
(Low IT Low TOT)

115

116

118

99

80

12
(High IT High TOT)

92

93.5

107

100

108

13
(Low IT Low TOT)

96

92.5

108

85

84

14
(Low IT Low TOT)

103

114.5

116

107

108

15
(High IT High TOT)

99

109

107

83

71

99.5

78
Family No.:
(Groups)

FSIQ

Reading
Composite

Math
Reasoning

Inattention

Impulsivity

16
(High IT High TOT

105

109

89

105

111

Note. FSIQ = Full Scale Intelligence Quotient; IT = Intrathecal chemotherapies; TOT = Time off
therapy.
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Table 7
Healthy Siblings: Mean Scores on Significant, Large, and Medium Effect Size Measures
FSIQ

Reading
Composite

1
(Low IT Low TOT)

96

95

85

93

79

2
(High IT High TOT)

108

114

115

71

94

3
(Low IT High TOT)

85

98

41

60

4
(High IT High TOT)

110

115

116

97

70

5
(Low IT Low TOT)

116

122

123

97

96

6
(High IT High TOT)

121

123

132

105

82

7
(Low IT High TOT)

102

102

102

63

52

8
(Low IT Low TOT)

114

110.5

110

71

62

9
(Low IT Low TOT)

112

111.5

126

63

82

10
(High IT High TOT)

112

113.5

106

99

86

11
(Low IT Low TOT)

108

107.5

96

103

104

12
(High IT High TOT)

110

113.5

112

82

85

13
(Low IT Low TOT)

104

91.5

95

95

104

14
(Low IT Low TOT)

105

102.5

103

87

111

15
(High IT High TOT)

114

110

121

101

98

Family No.:
(Groups)

94.5

Math
Inattention
Reasoning

Impulsivity

80
Family No.:
(Groups)
16
(High IT High TOT)

FSIQ

Reading
Composite

1

117.5

Math
Inattention
Reasoning

106

73

Impulsivity

103

Note. FSIQ = Full Scale Intelligence Quotient; IT = Intrathecal chemotherapies; TOT=Time off
therapy.
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Table 8
Difference Score Statistical Analyses for Numbers of Intrathecal Chemotherapy Treatments
High IT
(>20)
n=7

Low IT
(<19)
n=9

Domain
& Measure

M (SD)

M (SD)

t-test

Intelligence
Quotient: WISC-IV
Full Scale IQ

-8.71(10.22)

-.44(8.20)

1.798 .047

d=.89

Reading Composite:
WIAT-II
-7.36(6.54)

3.94(5.89)

3.633 .001*

d=1.81

Mathematics:
Math Reasoning

-8.85(6.04)

5.22(11.46)

3.079 .004*

d=1.61

Writing:
Three-Minute
Writing Sample

1.48(16.72)

-4.56(17.35)

.406 .345

d=.21

Inattention:
TOVA Omission

6.21(16.06) 19.52(25.65)

1.198 .125

d=.62

Impulsivity:
TOVA Commission -3.61(20.87) 11.67(24.86)

1.304 .107

d=.64

Processing Speed:
TOVA Response Time
Composite
6.00(16.54)

.61(24.17)

.504

.311

d=.26

p value

Cohen’s d

Verbal Memory:
CVLT List A 1-5

3.43(11.98)

3.00(22.02)

.046

.481

d=.02

Executive Function:
RCFT – Copy

0.52(3.73)

1.87(10.94)

.582

.285

d=.29

-4.35(15.79)
(n = 8)

.392

.278

d=.15

Executive Function:
BRIEF – Global
0.16(10.51)
Executive Composite (n = 6)

Note. M = mean difference score between sibling pairs based on a M of 100; SD = standard
deviation; a SD of 15; n = sample size; IT = Intrathecal chemotherapies; WISC-IV = Wechsler
Intelligence Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler
Individual Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT =
California Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior
Rating Inventory of Executive Functioning. * p = .005, one tailed t-test.

82
Table 9
Difference Score Statistical Analyses for Time off Therapy
High TOT
(>5 years)
n=9

Low TOT
(<5 years)
n=7

Domain:
Measure

M (SD)

M (SD)

t-test

p value

Intelligence
Quotient: WISC-IV
Full Scale IQ

-5.22(11.51)

-2.57(7.59)

.525

.304

d=.27

Reading Composite:
WIAT-II
-4.44(8.16)

3.43(6.56)

2.077

.028

d=1.06

Mathematics:
Math Reasoning

-6.67(6.09)

6.43(12.83) 2.791

.007

d=1.30

Writing:
Three-Minute
Writing Sample

-2.56(10.02)

-.185

.572

d=.09

Inattentiveness:
TOVA Omission

17.25(26.75)

9.14 (15.92)

.707

.246

d=.37

Impulsivity:
TOVA Commission 7.22(28.20)

2.11(18.30)

-.415

.342

d=.22

Processing Speed:
TOVA Response Time
Composite
7.36(14.89)

-2.68(26.63)

.960

.177

d=.47

Verbal Memory:
CVLT List A 1-5

2.00(22.06)

-.018

.507

d=.11

Executive Function:
RCFT – Copy
1.00(6.32)

1.65(10.99)

.601

.279

d=.30

Executive Function:
BRIEF – Global
-0.81(9.94)
Executive Composite (n = 8)

-4.02(17.02)
(n = 6)

.370

.337

d=.10

4.11(15.00)

-4.06(19.91)

Cohen’s d

Note. M = mean difference score between sibling pairs based on a M of 100; SD = standard
deviation; a SD of 15; n = sample size; IT = Intrathecal chemotherapies; WISC-IV = Wechsler
Intelligence Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler
Individual Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT =
California Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior
Rating Inventory of Executive Functioning. *p = .005, one tailed t-test.

83
Table 10
Wechsler Intelligence Scale for Children - Fourth Edition Subscale Scores

Intelligence
Quotient
Subscale
Children with ALL
Verbal
Comprehension
Index
Perceptual
Reasoning Index
Working Memory
Index
Processing Speed
Index
Siblings
Verbal
Comprehension
Index
Perceptual
Reasoning Index

High IT
(>20)
n=7

Low IT
(<19)
n=9

High TOT
(>5 years)
n=9

Low TOT
(<5 years)
n=7

M (SD)

M (SD)

M (SD)

M (SD)

105(13.85)

103.11(14.78)

104.11(17.93)

103.71(12.49)

103.71(11.14)

106.66(8.17)

103.33(9.97)

108(8.22)

100.42(4.75)

103.22(10.98)

103.57(12.66)

106.28(7.93)

93.28(8.15)

114.28(7.06)
108.57(4.96)

98(12.88)

93.88(8.84)

98.57(12.77)

107.33(12.40)

111.44(9.34)

109(12.90)

105.55(7.87)

106(6.83)

108(6.95)

Working Memory
Index

106.28(7.93)

101.44(14.54)

102.77(11.88)

104.57(13.03)

Processing Speed
Index

100.57(20.18)

96.11(9.30)

97.11(18.77)

99.28(7.91)

Note. M = mean; SD = standard deviation; n = sample size.
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Table 11
Children with ALL: WISC-IV Subscale Individual Scores
Family
No.

WISC-IV
. V.C
.

WISC-IV
P.R

.

WISC-IV
W.M

WISC IV
P.S.

WISC IV
FSIQ

1

95

100

120

106

105

2

110

117

102

103

112

3

81

96

102

83

87

4

106

98

102

80

98

5

112

117

91

94

108

6

124

121

102

94

116

7

121

108

102

109

114

8

124

110

94

75

105

9

102

104

102

106

105

10

98

94

94

88

92

11

110

121

120

91

115

12

87

92

107

94

92

13

87

102

91

112

96

14

96

102

107

106

103

15

91

102

102

103

99

16

119

102

94

91

105

Note. WISC IV V.C. = Wechsler Intelligence Scale for Children - Fourth Edition, Verbal
Comprehension Index; WISC P.R. = Wechsler Intelligence Scale for Children - Fourth Edition,
Perceptual Reasoning Index; WISC W.M. = Wechsler Intelligence Scale for Children - Fourth
Edition, Working Memory Index; WISC P.S. = Wechsler Intelligence Scale for Children - Fourth
Edition, Processing Speed Index; WISC FSIQ = Wechsler Intelligence Scale for Children Fourth Edition, Full Scale Intelligence Quotient.
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Table 12
Healthy Siblings: WISC-IV Subscale Individual Scores
WISC-IV

WISC-IV

WISC-IV

WISC-IV

V.C.

P.R.

W.M.

P.S.

FSIQ

IV1

96

102

88

100

96

2

112

115

94

97

108

3

93

94

77

85

85

4

114

104

107

103

110

5

128

112

102

100

116

6

124

115

116

109

121

7

110

100

104

85

102

8

119

115

107

97

114

9

119

106

126

83

112

10

106

108

107

115

112

11

104

98

116

106

108

12

110

104

116

100

110

13

95

117

94

106

104

14

102

106

99

103

105

15

110

110

102

121

114

16

124

104

102

59

100

Family
No.

WISC-IV

Note. WISC IV V.C. = Wechsler Intelligence Scale for Children - Fourth Edition, Verbal
Comprehension Index; WISC P.R. = Wechsler Intelligence Scale for Children - Fourth Edition,
Perceptual Reasoning Index; WISC W.M. = Wechsler Intelligence Scale for Children - Fourth
Edition, Working Memory Index; WISC P.S. = Wechsler Intelligence Scale for Children - Fourth
Edition, Processing Speed Index; WISC FSIQ = Wechsler Intelligence Scale for Children Fourth Edition, Full Scale Intelligence Quotient.
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Table 13
Sibling Pair Large Variability Data
Dependent
Variable:

Family Pair Number
Child with ALL Negative Skew

Full Scale IQ (#13) -20 high IT & high TOT
(#14) -18 high IT & high TOT
(#15) -15 high IT & high TOT

Family Pair Number
Child with ALL Positive Skew

(#9)

12

low IT & high TOT

(#15)

12

high IT & high TOT

Reading
Composite

(#14) -20 high IT & high TOT

Math
Reasoning

(#3) -15
(#16) -17

low IT & low TOT
high IT & high TOT

(#1)
(#4)

15
22

low IT & low TOT
low IT & low TOT

Total
Words
Written

(#1) -21
(#13) -19
(#4) -36

low IT & low TOT
high IT & high TOT
low IT & low TOT

(#6)

20

high IT & high TOT

TOVA
Inattention

(#16) -18

high IT & high TOT

(#8)
(#9)
(#14)
(#15)

69
43
18
20

low IT & high TOT
low IT & high TOT
high IT & high TOT
high IT & high TOT

TOVA
Impulsivity

(#11)
(#13)
(#4)
(#5)
(#15)

high IT & high TOT
high IT & high TOT
low IT & low TOT
low IT & low TOT
high IT & high TOT

(#1)
(#8)
(#9)
(#7)
(#3)
(#14)

17
50
40
18
15
23

low IT & low TOT
low IT & high TOT
low IT & high TOT
low IT & low TOT
low IT & low TOT
high IT & low TOT

-31
-16
-25
-20
-26

TOVA
Response
Time

(#1) -22
(#2) -34
(#7) -31

low IT & low TOT
low IT & low TOT
low IT & low TOT

(#10)
(#9)
(#4)
(#14)
(#5)

35
18
35
19
17

high IT & high TOT
low IT & high TOT
low IT & low TOT
high IT & high TOT
low IT & low TOT

CVLT List A

(#7) -13 low IT & low TOT

(#9)
(#3)
(#5)

19
15
23

low IT & high TOT
low IT & low TOT
low IT & low TOT

87
Dependent
Variable:

Family Pair Number
Survivor Negative Skew

RCFT – Copy (#11)
(#9)
(#7)
(#13)
(#16)

-25
-24
-30
-16
-20

Family Pair Number
Survivor Positive Skew

high IT & high TOT
low IT & high TOT
low IT & low TOT
high IT & high TOT
high IT & high TOT

(#1)
(#8)
(#3)
(#15)

20
22
29
34

low IT & low TOT
low IT & high TOT
low IT & low TOT
high IT & low TOT

BRIEF Parent (#11) -13 high IT & high TOT
Report

(#15)

51

high IT & high TOT

Note. IT = Intrathecal chemotherapies; TOT = Time off therapy.
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Table 14
Healthy Sibling and Post Therapy Children with ALL Attention Data: Reddick (2006)
Attention

Siblings (n = 33)
T Score

Survivors (n = 84)
T Score

Omissions (percentile)
D (attentiveness)a

80.75 ± 19.199*
57.47 ± 9.06

62.9 ± 8.7b*
57.6 ± 10.4b

a=attentiveness was measured as the time difference between the stimulus and non-stimulus item on the screen
(how often and how quickly the participant clicks the response button, when the target is not on the screen)
b=Statistically significant differences from test norms superscript symbols (P < 0.01) as analyzed in the

2006 study
*Scores of 60 or above indicate abnormally high inattention or impulsivity
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RESEARCH PROJECTS AND GRANTS
Wagner College 2014
New York Community Trust ($10,000). Reaching Learners with Special Needs through 21st
Century Technology Skills. This program provides a series of learning goals that allow special

124
needs students to take risks, socialize, and engage in collaborative conversations to strengthen
their digital media skills. In a format of three modules structured with technology teaching time
and socialization time to promote social and emotional learning, Wagner College undergraduate
and graduate students will assist in implementing the workshops.
Robinson Fellowship ($2,500). An Investigation of the Implicit and Explicit Components of
Democratic Engagement Taught Through Not-for-profit Educational Programs.
Virtual Visits Science Labs with New York Hall of science ($100,000). The goal of this pilot
program is to allow these students to get the science lab experiences they need virtually and still
graduate on time with a Regents Diploma. Wagner College Portion ($10,000).
HIVE NYC Grant with New York Hall of Science ($150,000). Air Casting for Middle School
Students. Wagner College portion ($9,000).
Silverman Family Foundation Grant with New York Hall of Science for virtual educational
programming for hospital and homebound children ($10,000). Through work with Living
Through Learning Foundation.
Wagner College 2013
HIVE NYC Grant with Parsons New School for Design ($100,000). gadgITERATION is a series
of hands-on, entry-level design workshops that encourage students’ creative and artistic
engagement with technology. Wagner College portion ($6,200).
HIVE NYC Grant with New York Hall of Science ($150,000). Air Casting for Middle School
Students. Wagner College portion ($9,000).
Silverman Family Foundation Grant with New York Hall of Science for virtual educational
programming for hospital and homebound children ($10,000). Through work with Living
Through Learning Foundation
Survivor Vision Foundation Research Grant for educational technology use by hospital teachers
Pilot study to direct creation of a phone application for hospital and home instruction teachers
($10,000).

MEDIA REPORTS
Lore, D. (2014, April 27). Wagner partners with Lifestyles for the Disabled. Staten Island
Advance. Available at
http://www.silive.com/news/index.ssf/2014/04/in_our_schools_wagner_college.html.
Lore, D. (2014, July 22) Wagner College hosts scholars from Obama's Young African Leaders
initiative. Staten Island Advance. Available at
http://www.silive.com/northshore/index.ssf/2014/07/wagner_college_hosts_group_fro.html.
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SERVICE
National
Founder and Executive Director, The Living Through Learning Foundation. 2008 – Present.
www.livingthroughlearning.org,
Reviewer & Advisory Board Member, 2014-15. Handbook of Research on Effective
Communication in Culturally Diverse Classrooms, Frumkin, R. and Gonzalez, K, eds.
Advances in Higher Education and Professional Development (AHEPD). Forthcoming
2015-16.
President Elect, Division for Physical Health and Multiple Disabilities, Council for Exceptional
Children (CEC), 2013-14.
o Review and approve all presentation for national CEC conference
o Organize and run all Executive board meetings
o Set national division agenda for 2015
o Collaborate with all committee chairs including journal editor, newsletter editor,
membership committee, by-laws committee, and special topics committees
Past President of Association of Pediatric Hematology Oncology Educational Specialists,
(2009 – 2012)
o Chaired Nominating Committee
o Provided counsel to current president and other board members
o Continue to provide leadership during national conference
Joint Committee member for Association of Pediatric Hematology Oncology Educational
Specialists and Association for the Education of Children with Medical Needs (2014 –
Present)
o One of seven individuals selected to provide recommendations to both organizations
around complex and sensitive issues such as joint conferences, joint legislative agendas,
and possible merger of the two organizations
Reviewer & Advisory Board Member, 2011. Controlling Complexities: Understanding the
Structures of Questions. Hardt, M. eds. Skill Plan. 2011.
Regional/Local
Provided test design & item design theory in-services for New World Prep Charter School
Co-ran the Collect, Construct, Change (C3) project with New World Prep Charter School
which aimed to: (1) equip youth with skills, knowledge, and tools to record, interpret,
and communicate air quality information; (2) furnish youth with learning experiences
that encourage them to engage with their environment, participate in community life,
and understand why science is important in solving real-world problems; and (3)
provide meaningful air quality information to the public and policy makers.
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College
Academic Review Committee (2012 – 2014)
Intermediate Learning Community Member (2013 – 2014)
First Year Program Member (2011, 2012, & 2014)
Advisor for new student organization, Exceeding the Expectations, focused on raising
disability awareness. (2014)
Lead Educator for one week in the Young African Leaders Institute (Summer, 2014)
2014 Diversity Action Council Award recipient
Department
Member, NCATE accreditation preparation team (2011-2012)
Lead, Council for Exceptional Children (CEC) Specialty Program Association Accreditation
Reports, grades 1-6 & 7-12 (2011-12)
Lead, Council for Exceptional Children (CEC) Specialty Program Association Accreditation
Reports, grades birth through 2 (2013-14)
Lead, student support, both individual and group, for certification exam preparation for the
Students with Disabilities CST Exam (2011-present)
Departmental advisement beyond assigned advisees (2011-present). Entrance and exit
interviews for undergraduate and graduate students, non-education students with an
interest in psychosocial employment (psychology, social work, child life therapy,
educational specialists) in hospital settings.

Professional Associations
Association of Pediatric Hematology Oncology Educational Specialists (APHOES). President
(2009 – 2012) & Founding Member (2005 – Present)
Association for the Education of Children with Medical Needs (AECMN). Member, Advocacy
Committee (2008 – Present)
Council For Exceptional Children (CEC) (2006-present)

